Contact Molecules for Homologous Proteins | ||||
![]() [Full Bars] |
![]() [SiteTable] |
|
![]() [Back to Search Page] |
![]() [Back to HOMCOS] |
![]() [SupCon3D] |
![]() [help] |
seq_id(%): [0] [30] [40] [50] [60] [70] [80] [90] [95] [100] | ![]() [show] [download] [help] |
PID | QueryLength | Homolgous Sequence in PDB | UniProt Query | TITLE |
2912825 | 359 | 500 | P30556(AGTR1_HUMAN) | RecName: Full=Type-1 angiotensin II receptor ;AltName: Full=AT1AR ;AltName: Full=AT1BR;AltName: Full=Angiotensin II type-1 receptor ; Short=AT1 receptor ; |
QUERYSEQ |
MILNSSTEDGIKRIQDDCPKAGRHNYIFVMIPTLYSIIFVVGIFGNSLVVIVIYFYMKLKTVASVFLLNLALADLCFLLTLPLWAVYTAMEYRWPFGNYLCKIASASVSFNLYASVFLLTCLSIDRYLAIVHPMKSRLRRTMLVAKVTCI IIWLLAGLASLPAIIHRNVFFIENTNITVCAFHYESQNSTLPIGLGLTKNILGFLFPFLIILTSYTLIWKALKKAYEIQKNKPRNDDIFKIIMAIVLFFFFSWIPHQIFTFLDVLIQLGIIRDCRIADIVDTAMPITICIAYFNNCLNPL FYGFLGKKFKRYFLQLLKYIPPKAKSHSNLSTKMSTLSYRPSDNVSSSTKKPAPCFEVE |
359 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
region | name | description |
![]() |
1-359 | CHAIN | /note="Type-1 angiotensin II receptor" /id="PRO_0000069153" |
![]() ![]() |
1-25 | TOPO_DOM | /note="Extracellular" ECO:0000269|PubMed:26420482, ECO:0000269|PubMed:30639100, ECO:0000269|PubMed:32079768, ECO:0007744|PDB:4YAY, ECO:0007744|PDB:4ZUD, ECO:0007744|PDB:6DO1, ECO:0007744|PDB:6OS0, ECO:0007744|PDB:6OS1, ECO:0007744|PDB:6OS2" |
![]() ![]() ![]() |
26-55 | TRANSMEM | /note="Helical; Name=1" ECO:0000269|PubMed:26420482, ECO:0000269|PubMed:30639100, ECO:0000269|PubMed:32079768, ECO:0007744|PDB:4YAY, ECO:0007744|PDB:4ZUD, ECO:0007744|PDB:6DO1, ECO:0007744|PDB:6OS0, ECO:0007744|PDB:6OS1, ECO:0007744|PDB:6OS2" |
![]() ![]() ![]() |
56-61 | TOPO_DOM | /note="Cytoplasmic" ECO:0000269|PubMed:26420482, ECO:0000269|PubMed:30639100, ECO:0000269|PubMed:32079768, ECO:0007744|PDB:4YAY, ECO:0007744|PDB:4ZUD, ECO:0007744|PDB:6DO1, ECO:0007744|PDB:6OS0, ECO:0007744|PDB:6OS1, ECO:0007744|PDB:6OS2" |
![]() ![]() ![]() |
62-89 | TRANSMEM | /note="Helical; Name=2" ECO:0000269|PubMed:26420482, ECO:0000269|PubMed:30639100, ECO:0000269|PubMed:32079768, ECO:0007744|PDB:4YAY, ECO:0007744|PDB:4ZUD, ECO:0007744|PDB:6DO1, ECO:0007744|PDB:6OS0, ECO:0007744|PDB:6OS1, ECO:0007744|PDB:6OS2" |
![]() ![]() ![]() |
90-98 | TOPO_DOM | /note="Extracellular" ECO:0000269|PubMed:26420482, ECO:0000269|PubMed:30639100, ECO:0000269|PubMed:32079768, ECO:0007744|PDB:4YAY, ECO:0007744|PDB:4ZUD, ECO:0007744|PDB:6DO1, ECO:0007744|PDB:6OS0, ECO:0007744|PDB:6OS1, ECO:0007744|PDB:6OS2" |
![]() ![]() ![]() |
99-125 | TRANSMEM | /note="Helical; Name=3" ECO:0000269|PubMed:26420482, ECO:0000269|PubMed:30639100, ECO:0000269|PubMed:32079768, ECO:0007744|PDB:4YAY, ECO:0007744|PDB:4ZUD, ECO:0007744|PDB:6DO1, ECO:0007744|PDB:6OS0, ECO:0007744|PDB:6OS1, ECO:0007744|PDB:6OS2" |
![]() ![]() ![]() |
126-141 | TOPO_DOM | /note="Cytoplasmic" ECO:0000269|PubMed:26420482, ECO:0000269|PubMed:30639100, ECO:0000269|PubMed:32079768, ECO:0007744|PDB:4YAY, ECO:0007744|PDB:4ZUD, ECO:0007744|PDB:6DO1, ECO:0007744|PDB:6OS0, ECO:0007744|PDB:6OS1, ECO:0007744|PDB:6OS2" |
![]() ![]() ![]() |
142-165 | TRANSMEM | /note="Helical; Name=4" ECO:0000269|PubMed:26420482, ECO:0000269|PubMed:30639100, ECO:0000269|PubMed:32079768, ECO:0007744|PDB:4YAY, ECO:0007744|PDB:4ZUD, ECO:0007744|PDB:6DO1, ECO:0007744|PDB:6OS0, ECO:0007744|PDB:6OS1, ECO:0007744|PDB:6OS2" |
![]() ![]() ![]() |
166-190 | TOPO_DOM | /note="Extracellular" ECO:0000269|PubMed:26420482, ECO:0000269|PubMed:30639100, ECO:0000269|PubMed:32079768, ECO:0007744|PDB:4YAY, ECO:0007744|PDB:4ZUD, ECO:0007744|PDB:6DO1, ECO:0007744|PDB:6OS0, ECO:0007744|PDB:6OS1, ECO:0007744|PDB:6OS2" |
![]() ![]() ![]() |
191-216 | TRANSMEM | /note="Helical; Name=5" ECO:0000269|PubMed:26420482, ECO:0000269|PubMed:30639100, ECO:0000269|PubMed:32079768, ECO:0007744|PDB:4YAY, ECO:0007744|PDB:4ZUD, ECO:0007744|PDB:6DO1, ECO:0007744|PDB:6OS0, ECO:0007744|PDB:6OS1, ECO:0007744|PDB:6OS2" |
![]() ![]() ![]() |
217-239 | TOPO_DOM | /note="Cytoplasmic" ECO:0000269|PubMed:26420482, ECO:0007744|PDB:4YAY, ECO:0007744|PDB:4ZUD" |
![]() ![]() ![]() |
240-268 | TRANSMEM | /note="Helical; Name=6" ECO:0000269|PubMed:26420482, ECO:0007744|PDB:4YAY, ECO:0007744|PDB:4ZUD" |
![]() ![]() ![]() |
269-278 | TOPO_DOM | /note="Extracellular" ECO:0000269|PubMed:26420482, ECO:0007744|PDB:4YAY, ECO:0007744|PDB:4ZUD" |
![]() ![]() ![]() |
279-304 | TRANSMEM | /note="Helical; Name=7" ECO:0000269|PubMed:26420482, ECO:0007744|PDB:4YAY, ECO:0007744|PDB:4ZUD" |
![]() ![]() |
305-359 | TOPO_DOM | /note="Cytoplasmic" ECO:0000269|PubMed:26420482, ECO:0007744|PDB:4YAY, ECO:0007744|PDB:4ZUD" |
![]() ![]() |
335-359 | REGION | /note="Disordered" |
![]() ![]() ![]() |
335-350 | COMPBIAS | /note="Polar residues" |
![]() ![]() ![]() |
15-15 | BINDING | /ligand="angiotensin II" /ligand_id="ChEBI:CHEBI:58506" ECO:0007744|PDB:6DO1" |
![]() ![]() ![]() |
17-17 | BINDING | /ligand="angiotensin II" /ligand_id="ChEBI:CHEBI:58506" ECO:0000305|PubMed:32079768, ECO:0007744|PDB:6DO1, ECO:0007744|PDB:6OS0" |
![]() ![]() ![]() |
167-167 | BINDING | /ligand="angiotensin II" /ligand_id="ChEBI:CHEBI:58506" ECO:0000305|PubMed:32079768, ECO:0007744|PDB:6DO1, ECO:0007744|PDB:6OS0" |
![]() ![]() ![]() |
182-182 | BINDING | /ligand="angiotensin II" /ligand_id="ChEBI:CHEBI:58506" ECO:0000305|PubMed:32079768, ECO:0007744|PDB:6DO1, ECO:0007744|PDB:6OS0" |
![]() ![]() ![]() |
183-183 | BINDING | /ligand="angiotensin II" /ligand_id="ChEBI:CHEBI:58506" ECO:0000305|PubMed:32079768, ECO:0007744|PDB:6DO1, ECO:0007744|PDB:6OS0" |
![]() ![]() ![]() |
184-184 | BINDING | /ligand="angiotensin II" /ligand_id="ChEBI:CHEBI:58506" ECO:0000305|PubMed:32079768, ECO:0007744|PDB:6DO1, ECO:0007744|PDB:6OS0" |
![]() ![]() ![]() |
199-199 | BINDING | /ligand="angiotensin II" /ligand_id="ChEBI:CHEBI:58506" ECO:0000305|PubMed:32079768, ECO:0007744|PDB:6DO1, ECO:0007744|PDB:6OS0" |
![]() ![]() ![]() |
355-355 | LIPID | /note="S-palmitoyl cysteine" |
![]() ![]() ![]() ![]() ![]() |
1-359 | DISORDER | predicted by DISOPRED |
![]() |
|||||||
359 | |||||||
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
pdb_id | a1 | identity[%]2 | description | |||
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | 99.4 | Angiotensin receptor AT1R | |||
1.a1:asym_id for the homologue. 2.identity[%]2:sequence identity between the query and the homologue. |
![]() |
|||||||
359 | pdb_id | contact mol | homologue | ||||
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
a3 | description | a4 | identity[%]5 | Ncon6 | description | |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | SAR1-AngII[8 aa] | A | 100.0 /99.4 |
23 /23 |
Angiotensin receptor AT1R |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAQ_HUMAN Guanine nucleotide-binding protein G(q) subunit al.. | A | 100.0 /99.4 |
20 /20 |
Angiotensin receptor AT1R |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E | Nanobody Nb.AT110i1[58 aa] | A | 100.0 /98.7 |
3 /3 |
AGTR1_HUMAN C562_ECOLX AGTR1_HUMAN Type-1 angiotensin II receptor,Soluble cytochrome .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | Nanobody Nb.AT110i1[125 aa] | A | 100.0 /98.7 |
21 /21 |
AGTR1_HUMAN C562_ECOLX AGTR1_HUMAN Type-1 angiotensin II receptor,Soluble cytochrome .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | Angiotensin II[8 aa] | A | 52.2 /38.2 |
23 /24 |
AGTR2_HUMAN Type-2 angiotensin II receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | ANGT_HUMAN Angiotensinogen[8 aa] | A | 100.0 /94.8 |
20 /26 |
AGTR1_HUMAN C562_ECOLX AGTR1_HUMAN Type-1 angiotensin II receptor,Soluble cytochrome .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | TRV023 peptide[8 aa] | A | 100.0 /94.8 |
16 /23 |
AGTR1_HUMAN C562_ECOLX AGTR1_HUMAN Type-1 angiotensin II receptor,Soluble cytochrome .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | TRV026 peptide[8 aa] | A | 100.0 /94.8 |
20 /27 |
AGTR1_HUMAN C562_ECOLX AGTR1_HUMAN Type-1 angiotensin II receptor,Soluble cytochrome .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | AT118-L Nanobody[112 aa] | A | 100.0 /94.5 |
16 /23 |
AGTR1_HUMAN C562_ECOLX AGTR1_HUMAN Type-1 angiotensin II receptor Soluble cytochrome .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | LRH7-C2[2 aa] | C | 0.0 /41.8 |
1 /9 |
CML1_HUMAN C562_ECOLX CML1_HUMAN Chemerin-like receptor 1,Soluble cytochrome b562 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | FabH[220 aa] | A | 21.4 /38.4 |
14 /18 |
AGTR2_HUMAN C562_ECOLX AGTR2_HUMAN Type-2 angiotensin II receptor,Soluble cytochrome .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | FabL[212 aa] | A | 50.0 /38.4 |
2 /5 |
AGTR2_HUMAN C562_ECOLX AGTR2_HUMAN Type-2 angiotensin II receptor,Soluble cytochrome .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | C562_ECOLX C562_ECOLX Soluble cytochrome b562,Soluble cytochrome b562[59.. | A | 33.3 /38.2 |
3 /4 |
AGTR2_HUMAN Type-2 angiotensin II receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 45.5 /32.4 |
22 /22 |
CCL3_HUMAN CCR5_HUMAN C-C motif chemokine 3,C-C chemokine receptor type .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 31.6 /33.3 |
19 /19 |
CCR5_HUMAN C-C chemokine receptor type 5 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 20.0 /33.3 |
15 /17 |
C562_ECOLX SSR2_HUMAN Soluble cytochrome b562,Somatostatin receptor type.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 35.3 /33.3 |
17 /18 |
NPY1R_HUMAN Neuropeptide Y receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | D | 41.4 /35.6 |
29 /29 |
CX3C1_HUMAN CX3C chemokine receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 30.8 /29.9 |
13 /16 |
NPY2R_HUMAN Neuropeptide Y receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 26.1 /35.2 |
23 /23 |
OPRK_HUMAN Kappa-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | B | 21.4 /31.8 |
14 /15 |
C3AR_HUMAN C3a anaphylatoxin chemotactic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 21.4 /24.5 |
14 /16 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 17.6 /24.5 |
17 /17 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2,hydroxycarboxyli.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 33.3 /31.9 |
18 /18 |
CCL1_HUMAN CCR8_HUMAN A0A6M5E0N3_ADE02 C-C motif chemokine 1,C-C chemokine receptor type .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 26.7 /34.6 |
15 /15 |
FPR2_HUMAN N-formyl peptide receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 26.7 /36.0 |
15 /15 |
ADRB2_HUMAN SSR5_HUMAN Beta-2 adrenergic receptor,Somatostatin receptor t.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 35.0 /33.2 |
20 /20 |
OPRD_HUMAN Delta-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 31.6 /27.8 |
19 /21 |
HCAR1_HUMAN Hydroxycarboxylic acid receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 36.8 /38.2 |
19 /19 |
CML2_HUMAN Chemerin-like receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | RARR2_HUMAN Retinoic acid receptor responder protein 2[103 aa].. | A | 17.4 /38.2 |
23 /38 |
CML2_HUMAN Chemerin-like receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | G protein subunit q[228 aa] | E | 44.8 /36.6 |
29 /29 |
GPER1_HUMAN G-protein coupled estrogen receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | agonist peptide[17 aa] | B | 52.4 /37.6 |
21 /26 |
APJ_HUMAN RUBR_CLOPA APJ_HUMAN Apelin receptor,Rubredoxin,Apelin receptor Chimera.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 21.1 /38.5 |
19 /19 |
CML2_HUMAN Chemerin-like receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 35.3 /37.5 |
17 /17 |
CXCR4_HUMAN C-X-C chemokine receptor type 4 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | RARR2_HUMAN Retinoic acid receptor responder protein 2[108 aa].. | E | 15.4 /37.2 |
26 /26 |
CML1_HUMAN Chemerin-like receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | ARRB1_BOVIN Beta-arrestin-1[339 aa] | E | 37.5 /37.1 |
16 /23 |
ACKR3_HUMAN Atypical chemokine receptor 3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | SDF1_HUMAN SDF-1-beta(3-72)[14 aa] | E | 26.3 /37.1 |
19 /20 |
ACKR3_HUMAN Atypical chemokine receptor 3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | SDF1_HUMAN Stromal cell-derived factor 1[68 aa] | A | 28.6 /34.0 |
21 /30 |
ACKR3_HUMAN Atypical chemokine receptor 3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | SDF1_HUMAN Stromal cell-derived factor 1[62 aa] | A | 25.9 /37.5 |
27 /27 |
CXCR4_HUMAN C-X-C chemokine receptor type 4 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E | SDF1_HUMAN Stromal cell-derived factor 1[65 aa] | A | 15.8 /37.1 |
19 /19 |
CXCR4_HUMAN C-X-C chemokine receptor type 4 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | D | 45.0 /38.4 |
20 /20 |
CXCR4_HUMAN C-X-C chemokine receptor type 4 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | REGN7663 Fab light chain[219 aa] | C | 0.0 /37.1 |
4 /4 |
CXCR4_HUMAN C-X-C chemokine receptor type 4 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | REGN7663 Fab heavy chain[219 aa] | C | 19.0 /37.1 |
21 /21 |
CXCR4_HUMAN C-X-C chemokine receptor type 4 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | GNAO_HUMAN GNAO_HUMAN Guanine nucleotide-binding protein G(o) subunit al.. | F | 58.8 /36.3 |
17 /18 |
CCR6_HUMAN C-C chemokine receptor type 6,C-C chemokine recept.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | A0A1W2PS82_HUMAN GNAO_HUMAN Guanine nucleotide-binding protein G(o) subunit al.. | B | 50.0 /27.9 |
14 /16 |
GHSR_HUMAN Growth hormone secretagogue receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | A0A1W2PRJ7_HUMAN A0A1W2PP38_HUMAN GNAO_HUMAN G protein subunit alpha o1,Guanine nucleotide-bind.. | D | 30.0 /32.3 |
20 /21 |
GALR1_HUMAN Galanin receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAO_HUMAN GNAO_HUMAN GNAO_HUMAN Guanine nucleotide-binding protein G(o) subunit al.. | F | 35.7 /33.7 |
14 /15 |
SSR2_HUMAN Somatostatin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAO_HUMAN GNAO_HUMAN Guanine nucleotide-binding protein G(o) subunit al.. | A | 11.1 /30.0 |
18 /18 |
C5AR1_MOUSE C5a anaphylatoxin chemotactic receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAO_HUMAN GNAO_HUMAN Guanine nucleotide-binding protein G(o) subunit al.. | E | 25.0 /32.1 |
16 /17 |
C3AR_HUMAN C3a anaphylatoxin chemotactic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAO_HUMAN GNAO_HUMAN Guanine nucleotide-binding protein G(o) subunit al.. | E | 28.6 /24.2 |
21 /21 |
ACM4_HUMAN HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | GNAO_HUMAN Guanine nucleotide-binding protein G(o) subunit al.. | C | 37.5 /36.5 |
16 /16 |
CXCR2_HUMAN C-X-C chemokine receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAO_HUMAN Guanine nucleotide-binding protein G(o) subunit al.. | E | 28.6 /37.6 |
21 /21 |
CXCR3_HUMAN C-X-C chemokine receptor type 3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | CID25 Fab heavy chain[211 aa] | A | 33.3 /37.0 |
9 /12 |
ACKR3_HUMAN Atypical chemokine receptor 3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | RARR2_HUMAN Retinoic acid receptor responder protein 2[9 aa] | B | 17.4 /36.9 |
23 /23 |
CML1_HUMAN Chemerin-like receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | RARR2_HUMAN Retinoic acid receptor responder protein 2[9 aa] | A | 27.8 /38.5 |
18 /19 |
CML2_HUMAN Chemerin-like receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E | Chemerin 9[9 aa] | A | 23.5 /36.9 |
17 /18 |
CML1_HUMAN Chemerin-like receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 39.1 /36.9 |
23 /23 |
CML1_HUMAN Chemerin-like receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | Sar1, Ile8-angiotensin II[8 aa] | A | 58.3 /38.4 |
12 /22 |
AGTR2_HUMAN C562_ECOLX AGTR2_HUMAN Type-2 angiotensin II receptor,Soluble cytochrome .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H | Angiotensin-like peptide S1I8[8 aa] | A | 100.0 /98.7 |
26 /26 |
AGTR1_HUMAN C562_ECOLX AGTR1_HUMAN Type-1 angiotensin II receptor,Soluble cytochrome .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 26.7 /35.9 |
15 /15 |
FPR1_HUMAN fMet-Leu-Phe receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | D | 27.3 /35.2 |
22 /22 |
C562_ECOLX CXCR3_HUMAN LUCI_OPLGR Soluble cytochrome b562,C-X-C chemokine receptor t.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | CXL10_HUMAN C-X-C motif chemokine 10[8 aa] | D | 28.6 /36.9 |
14 /17 |
C562_ECOLX CXCR3_HUMAN LUCI_OPLGR Soluble cytochrome b562,C-X-C chemokine receptor t.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | CCL15_HUMAN CCL15(26-92)[65 aa] | E | 34.5 /36.8 |
29 /35 |
CCR1_HUMAN C-C chemokine receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | Nanobody 6[117 aa] | A | 18.2 /36.0 |
11 /13 |
OPRK_HUMAN Kappa opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | Nb6[116 aa] | A | 12.5 /27.8 |
8 /9 |
alpha1A-adrenergic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | Nb6[114 aa] | B | 18.2 /36.4 |
11 /12 |
C562_ECOLX CXCR3_HUMAN OPRK_HUMAN CXCR3_HUMAN Soluble cytochrome b562,C-X-C chemokine receptor t.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | REGN7663 Fab light chain[111 aa] | C | 0.0 /36.4 |
6 /6 |
CXCR4_HUMAN C-X-C chemokine receptor type 4 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | REGN7663 Fab light chain[112 aa] | C | 0.0 /36.6 |
2 /3 |
CXCR4_HUMAN C-X-C chemokine receptor type 4 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | REGN7663 Fab heavy chain[125 aa] | C | 16.7 /36.4 |
24 /24 |
CXCR4_HUMAN C-X-C chemokine receptor type 4 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | F | 33.3 /36.5 |
21 /21 |
CXCR2_HUMAN C-X-C chemokine receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | IL8_HUMAN Interleukin-8[71 aa] | F | 13.3 /36.5 |
15 /27 |
CXCR2_HUMAN C-X-C chemokine receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E | IL8_HUMAN Interleukin-8[67 aa] | F | 0.0 /36.5 |
2 /2 |
CXCR2_HUMAN C-X-C chemokine receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | IL8_HUMAN Interleukin-8[69 aa] | A | 11.8 /35.0 |
17 /25 |
CXCR1_HUMAN C-X-C chemokine receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | IL8_HUMAN MDNCF-a[73 aa] | A | 12.5 /36.5 |
24 /34 |
CXCR2_HUMAN C-X-C chemokine receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | IL8_HUMAN MDNCF-a[65 aa] | A | 0.0 /36.5 |
3 /3 |
CXCR2_HUMAN C-X-C chemokine receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | CXCL2_HUMAN C-X-C motif chemokine 2[69 aa] | A | 16.0 /36.5 |
25 /32 |
CXCR2_HUMAN C-X-C chemokine receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | CXCL2_HUMAN C-X-C motif chemokine 2[60 aa] | A | 0.0 /36.5 |
2 /2 |
CXCR2_HUMAN C-X-C chemokine receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GROA_HUMAN Growth-regulated alpha protein[68 aa] | C | 12.5 /36.5 |
24 /29 |
CXCR2_HUMAN C-X-C chemokine receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GROA_HUMAN Growth-regulated alpha protein[61 aa] | C | 0.0 /36.5 |
2 /2 |
CXCR2_HUMAN C-X-C chemokine receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | CXCL3_HUMAN C-X-C motif chemokine 3[53 aa] | C | 0.0 /36.5 |
1 /1 |
CXCR2_HUMAN C-X-C chemokine receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | CXCL3_HUMAN C-X-C motif chemokine 3[67 aa] | C | 14.3 /36.5 |
21 /27 |
CXCR2_HUMAN C-X-C chemokine receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | CXCL6_HUMAN C-X-C motif chemokine 6[65 aa] | B | 18.2 /36.5 |
22 /27 |
CXCR2_HUMAN C-X-C chemokine receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | CXCL5_HUMAN C-X-C motif chemokine 5[65 aa] | B | 15.8 /36.5 |
19 /24 |
CXCR2_HUMAN C-X-C chemokine receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | CXCL5_HUMAN C-X-C motif chemokine 5[65 aa] | B | 0.0 /36.5 |
2 /2 |
CXCR2_HUMAN C-X-C chemokine receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | Nanobody 6M[117 aa] | A | 18.2 /34.3 |
11 /12 |
OPRM_HUMAN Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | Nanobody 6M[117 aa] | A | 16.7 /36.4 |
12 /13 |
Kappa-Opioid Receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | CCL20_HUMAN C-C motif chemokine 20[66 aa] | F | 18.8 /36.3 |
16 /25 |
CCR6_HUMAN C-C chemokine receptor type 6,C-C chemokine recept.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | Nb6[101 aa] | B | 20.0 /36.2 |
10 /11 |
C562_ECOLX CXCR3_HUMAN OPRK_HUMAN CXCR3_HUMAN Soluble cytochrome b562,C-X-C chemokine receptor t.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | A0A096MZM0_PAPAN G protein subunit alpha i1[224 aa] | D | 31.2 /36.1 |
16 /16 |
C562_ECOLX APJ_HUMAN Soluble cytochrome b562,Apelin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 46.7 /36.1 |
15 /17 |
APJ_HUMAN Apelin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | APEL_HUMAN Apelin-13[13 aa] | E | 44.4 /36.1 |
27 /27 |
APJ_HUMAN Apelin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E | octreotide[6 aa] | A | 0.0 /36.0 |
10 /12 |
ADRB2_HUMAN SSR5_HUMAN Beta-2 adrenergic receptor,Somatostatin receptor t.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | ACE-TYR-ALA-DTY-THR-THR-CYS-THR-DPN-XT9[10 aa] | E | 17.4 /35.9 |
23 /23 |
OPRK_HUMAN Kappa-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 36.4 /35.9 |
22 /22 |
C562_ECOLX CCR8_HUMAN Soluble cytochrome b562,C-C chemokine receptor typ.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | Peptide agonist fMIFL[4 aa] | A | 33.3 /35.9 |
15 /16 |
FPR1_HUMAN fMet-Leu-Phe receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | D | 42.1 /37.6 |
19 /19 |
CCR1_HUMAN C-C chemokine receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 26.1 /35.9 |
23 /23 |
APJ_HUMAN Apelin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | WN561[14 aa] | A | 48.1 /35.9 |
27 /27 |
APJ_HUMAN Apelin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | MM07[13 aa] | A | 40.0 /35.9 |
25 /25 |
APJ_HUMAN Apelin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | WN353[13 aa] | A | 39.1 /35.9 |
23 /24 |
APJ_HUMAN Apelin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | Peptide Agonist fMLF[3 aa] | A | 41.7 /35.9 |
12 /13 |
FPR1_HUMAN fMet-Leu-Phe receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E | FME-LEU-PHE[3 aa] | A | 40.0 /35.7 |
10 /11 |
FPR1_HUMAN fMet-Leu-Phe receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 27.8 /35.7 |
18 /18 |
FPR1_HUMAN fMet-Leu-Phe receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 41.2 /35.7 |
17 /17 |
CML1_HUMAN Chemerin-like receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | RARR2_HUMAN Retinoic acid receptor responder protein 2 chemeri.. | A | 17.6 /35.7 |
34 /38 |
CML1_HUMAN Chemerin-like receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H | ELA_HUMAN Apelin receptor early endogenous ligand[15 aa] | D | 50.0 /35.6 |
18 /18 |
C562_ECOLX APJ_HUMAN Soluble cytochrome b562,Apelin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 18.2 /35.6 |
11 /12 |
C562_ECOLX APJ_HUMAN Soluble cytochrome b562,Apelin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | FME-TYR-PHE-ILE-ASN-ILE-LEU-THE-LEU[7 aa] | B | 42.1 /35.7 |
19 /21 |
C562_ECOLX FPR2_HUMAN Soluble cytochrome b562,N-formyl peptide receptor .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | HUNIN_HUMAN Humanin[15 aa] | B | 35.0 /35.7 |
20 /23 |
C562_ECOLX FPR2_HUMAN Soluble cytochrome b562,N-formyl peptide receptor .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | CID24 Fab heavy chain[220 aa] | A | 14.8 /34.3 |
27 /29 |
ACKR3_HUMAN Atypical chemokine receptor 3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | CID24 Fab light chain[211 aa] | A | 0.0 /34.3 |
6 /6 |
ACKR3_HUMAN Atypical chemokine receptor 3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | CID25 Fab light chain[211 aa] | A | 50.0 /37.0 |
2 /2 |
ACKR3_HUMAN Atypical chemokine receptor 3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | D | 46.2 /35.6 |
13 /14 |
C562_ECOLX APJ_HUMAN Soluble cytochrome b562,Apelin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | G alpha gustducin protein[205 aa] | A | 28.6 /35.6 |
21 /21 |
OPRK_HUMAN Kappa-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | Single domain antibody JN241[129 aa] | A | 26.9 /37.6 |
26 /32 |
APJ_HUMAN RUBR_CLOPA APJ_HUMAN Apelin receptor,Rubredoxin,Apelin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | JN241[129 aa] | C | 24.0 /35.6 |
25 /32 |
C562_ECOLX APJ_HUMAN Soluble cytochrome b562,Apelin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 41.7 /35.6 |
12 /13 |
C562_ECOLX APJ_HUMAN Soluble cytochrome b562,Apelin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | APEL_HUMAN Apelin-13[13 aa] | D | 56.0 /36.1 |
25 /26 |
C562_ECOLX APJ_HUMAN Soluble cytochrome b562,Apelin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | A0A096MZM0_PAPAN G protein subunit alpha i1[224 aa] | D | 25.0 /35.6 |
20 /21 |
C562_ECOLX APJ_HUMAN Soluble cytochrome b562,Apelin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 28.6 /35.3 |
21 /22 |
OPRM_MOUSE Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 28.6 /35.3 |
21 /21 |
C562_ECOLX OPRM_MOUSE Soluble cytochrome b562, Mu-type opioid receptor c.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | C | 34.8 /35.1 |
23 /24 |
OPRK_HUMAN Kappa-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | B | 22.2 /35.4 |
18 /18 |
CML2_HUMAN G-protein coupled receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | RARR2_HUMAN Retinoic acid receptor responder protein 2[137 aa].. | B | 17.9 /35.4 |
39 /39 |
CML2_HUMAN G-protein coupled receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | G subunit q (Gi1-Gq chimeric)[230 aa] | D | 41.4 /35.3 |
29 /30 |
BKRB2_HUMAN B2 bradykinin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | CCL2_HUMAN C-C motif chemokine 2[69 aa] | A | 25.0 /35.3 |
20 /26 |
CCR2_HUMAN Isoform B of C-C chemokine receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 41.2 /35.3 |
17 /17 |
CCR2_HUMAN Isoform B of C-C chemokine receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 25.0 /34.1 |
24 /24 |
OPRM_HUMAN Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 36.8 /35.3 |
19 /20 |
OPRK_HUMAN Kappa-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | PDYN_HUMAN Dynorphin[8 aa] | A | 26.3 /35.3 |
19 /20 |
OPRK_HUMAN Kappa-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 26.3 /35.3 |
19 /19 |
OPRK_HUMAN Kappa-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 30.8 /35.3 |
26 /27 |
OPRK_HUMAN Kappa-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 30.0 /35.3 |
20 /21 |
OPRK_HUMAN Kappa-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | Guanine nucleotide-binding protein G(q) subunit al.. | F | 38.5 /30.4 |
26 /29 |
Neuromedin-U receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | Guanine nucleotide-binding protein G(q) subunit al.. | D | 33.3 /29.2 |
24 /29 |
BRS3_HUMAN Bombesin receptor subtype-3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | G-alpha q[232 aa] | E | 36.4 /35.2 |
22 /23 |
CLTR2_HUMAN Cysteinyl leukotriene receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAZ_HUMAN Guanine nucleotide-binding protein G(z) subunit al.. | A | 27.8 /35.2 |
18 /19 |
OPRK_HUMAN Kappa-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E | CXL11_HUMAN C-X-C motif chemokine 11[73 aa] | D | 25.0 /35.2 |
28 /31 |
C562_ECOLX CXCR3_HUMAN LUCI_OPLGR Soluble cytochrome b562,C-X-C chemokine receptor t.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | GNAO_HUMAN Guanine nucleotide-binding protein G(o) subunit al.. | E | 28.6 /35.2 |
21 /21 |
OPRK_HUMAN Kappa-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | D | 30.8 /35.1 |
26 /27 |
C562_ECOLX OPRM_MOUSE Soluble cytochrome b562,Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | Dynorphin[9 aa] | C | 17.4 /35.1 |
23 /24 |
OPRK_HUMAN Kappa-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | Nanobody E (NbE)[125 aa] | A | 10.0 /35.1 |
20 /20 |
OPRM_MOUSE Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | Guanine nucleotide-binding protein G(i) subunit al.. | F | 23.5 /35.1 |
17 /18 |
SSR5_HUMAN Somatostatin receptor type 5 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | CORT_HUMAN Cortistatin[12 aa] | F | 13.6 /35.1 |
22 /25 |
SSR5_HUMAN Somatostatin receptor type 5 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | Megabody 6[65 aa] | A | 11.1 /35.0 |
9 /10 |
OPRM_MOUSE Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 28.6 /35.0 |
21 /21 |
CXCR1_HUMAN C-X-C chemokine receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | Nanobody 39[118 aa] | A | 34.8 /34.9 |
23 /23 |
OPRM_MOUSE Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | Nanobody[122 aa] | A | 55.0 /36.9 |
20 /21 |
C562_ECOLX OPRK_HUMAN Soluble cytochrome b562, kappa-type opioid recepto.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | Nanobody39[109 aa] | A | 60.0 /37.3 |
15 /16 |
OPRK_HUMAN Kappa-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | kappa opioid receptor Nanobody 6[52 aa] | B | 22.2 /34.8 |
9 /10 |
OPRM_MOUSE Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E | Octreotide[8 aa] | F | 5.6 /33.7 |
18 /18 |
SSR2_HUMAN Somatostatin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | octreotide[8 aa] | E | 0.0 /34.7 |
9 /11 |
SSR5_HUMAN Somatostatin receptor type 5 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | somatostatin-14[12 aa] | D | 7.7 /34.7 |
13 /13 |
SSR2_HUMAN Somatostatin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | Guanine nucleotide-binding protein G(i) subunit al.. | E | 20.0 /34.7 |
10 /11 |
SSR5_HUMAN Somatostatin receptor type 5 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 42.9 /34.7 |
21 /21 |
GPR15 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | GP15L_HUMAN Protein GPR15LG[10 aa] | E | 30.0 /34.7 |
20 /20 |
GPR15 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | Polyphemusin analog, CXC chemokine receptor antago.. | A | 19.2 /34.7 |
26 /26 |
CXCR4_HUMAN LYS_BPT4 CXCR4_HUMAN C-X-C chemokine receptor type 4, Lysozyme Chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | DAMGO[4 aa] | E | 23.1 /34.7 |
13 /13 |
OPRM_HUMAN Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | SDF1_HUMAN Stromal cell-derived factor 1[59 aa] | A | 20.6 /34.6 |
34 /43 |
ACKR3_HUMAN Atypical chemokine receptor 3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | Synthetic peptide[5 aa] | E | 45.0 /35.7 |
20 /23 |
FPR1_HUMAN fMet-Leu-Phe receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | Synthetic peptide[5 aa] | A | 33.3 /34.3 |
15 /17 |
FPR2_HUMAN N-formyl peptide receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | FME-LEU-PHE-ILE-ILE[5 aa] | B | 31.6 /34.6 |
19 /20 |
C562_ECOLX FPR2_HUMAN Soluble cytochrome b562,N-formyl peptide receptor .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAI2_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | B | 31.6 /34.6 |
19 /19 |
C562_ECOLX FPR2_HUMAN Soluble cytochrome b562,N-formyl peptide receptor .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | B4DMD5_HUMAN Amyloid-beta A4 protein[16 aa] | B | 30.8 /34.6 |
26 /28 |
C562_ECOLX FPR2_HUMAN Soluble cytochrome b562,N-formyl peptide receptor .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | VMI2_HHV8P Viral macrophage inflammatory protein 2[70 aa] | A | 28.0 /34.5 |
25 /26 |
CXCR4_HUMAN LYS_BPT4 CXCR4_HUMAN C-X-C chemokine receptor type 4/Endolysin chimeric.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | F | 38.9 /34.4 |
18 /19 |
OPRM_HUMAN Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | F | 46.7 /34.4 |
15 /16 |
OPRM_HUMAN Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | F | 36.8 /34.4 |
19 /20 |
OPRM_HUMAN Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | endomorphin[5 aa] | A | 23.5 /34.4 |
17 /17 |
OPRM_HUMAN Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 30.0 /34.4 |
20 /21 |
OPRM_HUMAN Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
I | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | G | 47.1 /34.4 |
17 /18 |
OPRM_HUMAN Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | LYS-ARG-PRO-PRO-GLY-PHE-SER-PRO-PHE[9 aa] | A | 33.3 /34.4 |
24 /26 |
BKRB1_HUMAN B1 bradykinin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | G subunit q (Gi1-Gq chimeric)[235 aa] | A | 50.0 /34.4 |
24 /25 |
BKRB1_HUMAN B1 bradykinin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | ARG-PRO-PRO-GLY-PHE-SER-PRO-PHE-ARG[9 aa] | D | 41.7 /35.3 |
24 /24 |
BKRB2_HUMAN B2 bradykinin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | Bradykinin[9 aa] | A | 40.0 /34.4 |
25 /25 |
Bradykinin receptor BK2R |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAQ_HUMAN Guanine nucleotide-binding protein G(q) subunit al.. | A | 48.0 /34.4 |
25 /26 |
Bradykinin receptor BK2R |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | Kallidin[10 aa] | A | 35.7 /34.4 |
28 /29 |
Bradykinin receptor BK2R |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAQ_HUMAN Guanine nucleotide-binding protein G(q) subunit al.. | A | 48.3 /34.4 |
29 /30 |
Bradykinin receptor BK2R |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | TRP-LYS-TYR-MET-VAL-QXV[6 aa] | A | 23.8 /35.3 |
21 /23 |
C562_ECOLX FPR2_HUMAN Soluble cytochrome b562,N-formyl peptide receptor .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | Peptide agonist[6 aa] | A | 20.0 /34.3 |
15 /17 |
FPR2_HUMAN N-formyl peptide receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 24.0 /34.3 |
25 /25 |
FPR2_HUMAN N-formyl peptide receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | F | 27.3 /34.3 |
22 /22 |
FPR2_HUMAN N-formyl peptide receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E | Synthetic peptide[8 aa] | F | 27.8 /34.3 |
18 /20 |
FPR2_HUMAN N-formyl peptide receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 25.0 /34.2 |
20 /20 |
SSR4_HUMAN Somatostatin receptor type 4 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 36.4 /34.2 |
22 /23 |
ADRB2_HUMAN SSR5_HUMAN Beta-2 adrenergic receptor,Somatostatin receptor t.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | 004-DTR-LYS-TYR-PHA-HYP[6 aa] | E | 5.3 /34.2 |
19 /20 |
ADRB2_HUMAN SSR5_HUMAN Beta-2 adrenergic receptor,Somatostatin receptor t.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | DAMGO[5 aa] | E | 26.7 /35.3 |
15 /15 |
OPRM_MOUSE Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | DAMGO[5 aa] | A | 26.7 /34.2 |
15 /15 |
C562_ECOLX OPRM_HUMAN Soluble cytochrome b562,Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | F6VL43_MACMU G protein subunit alpha i3[224 aa] | A | 28.6 /34.2 |
21 /22 |
C562_ECOLX OPRM_HUMAN Soluble cytochrome b562,Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | Peptide agonist KGCHM07[5 aa] | A | 38.1 /32.5 |
21 /21 |
Delta opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | CYN 154806[10 aa] | A | 20.0 /34.1 |
20 /23 |
SSR2_HUMAN XYNA_BACCI SSR2_HUMAN Somatostatin receptor type 2,Endo-1,4-beta-xylanas.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 19.0 /33.5 |
21 /22 |
SSR2_HUMAN Somatostatin receptor type 2,LargeBit |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | Octreotide[7 aa] | A | 15.8 /34.1 |
19 /19 |
SSR2_HUMAN Somatostatin receptor type 2,LargeBit |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | Lanreotide[6 aa] | A | 6.7 /34.1 |
15 /15 |
SSR2_HUMAN Somatostatin receptor type 2,LargeBit |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 30.4 /34.4 |
23 /24 |
OPRM_HUMAN Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 27.3 /34.1 |
22 /23 |
OPRM_HUMAN Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | G | 0.0 /34.1 |
1 /1 |
OPRM_HUMAN Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | COLI_HUMAN Beta-endorphin[21 aa] | A | 17.6 /34.1 |
17 /17 |
OPRM_HUMAN Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | CID25 Fab light chain[105 aa] | A | 50.0 /34.0 |
2 /2 |
ACKR3_HUMAN Atypical chemokine receptor 3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E | CID24 Fab light chain[106 aa] | A | 0.0 /34.0 |
6 /6 |
ACKR3_HUMAN Atypical chemokine receptor 3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | CID25 Fab heavy chain[123 aa] | A | 33.3 /34.0 |
12 /15 |
ACKR3_HUMAN Atypical chemokine receptor 3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | CID24 Fab heavy chain[125 aa] | A | 14.8 /34.0 |
27 /30 |
ACKR3_HUMAN Atypical chemokine receptor 3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | Fab3949 H[219 aa] | A | 33.3 /33.8 |
3 /13 |
PAR2_HUMAN C562_ECOLX PAR2_HUMAN Proteinase-activated receptor 2,Soluble cytochrome.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | Fab3949 L[213 aa] | A | 50.0 /33.8 |
2 /9 |
PAR2_HUMAN C562_ECOLX PAR2_HUMAN Proteinase-activated receptor 2,Soluble cytochrome.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | bifunctional peptide[5 aa] | A | 16.7 /34.3 |
12 /12 |
C562_ECOLX Soluble cytochrome b562,Delta-type opioid receptor.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E | SMS_HUMAN Somatostatin-14[14 aa] | A | 19.0 /33.1 |
21 /21 |
SSR2_HUMAN OPRK_HUMAN SSR2_HUMAN Somatostatin receptor type 2,Kappa-type opioid rec.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | somatostatin-14[14 aa] | B | 17.4 /33.3 |
23 /23 |
SSR2_HUMAN Somatostatin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E | SMS_HUMAN Somatostatin-14[14 aa] | A | 23.1 /33.5 |
26 /26 |
SSR2_HUMAN Somatostatin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 26.3 /33.5 |
19 /19 |
SSR2_HUMAN Somatostatin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | G-alpha-i[236 aa] | A | 35.3 /35.7 |
17 /19 |
SSR1_HUMAN Somatostatin receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | G-alpha i[236 aa] | A | 35.7 /33.5 |
14 /18 |
SSR3_HUMAN Somatostatin receptor type 3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | 004-DTR-LYS-TY5-PHE-A1D5E[6 aa] | A | 15.8 /35.7 |
19 /20 |
SSR1_HUMAN Somatostatin receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | Pasireotide[6 aa] | A | 18.2 /33.5 |
22 /22 |
SSR3_HUMAN Somatostatin receptor type 3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | NIT-FC0-NLE-A1D5B[4 aa] | A | 5.6 /33.5 |
18 /18 |
SSR3_HUMAN Somatostatin receptor type 3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E | Octreotide[8 aa] | F | 9.5 /33.0 |
21 /21 |
SSR2_HUMAN OPRK_HUMAN SSR2_HUMAN Somatostatin receptor type 2,Kappa-type opioid rec.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | DPN-CYS-PHE-DTR-LYS-THR-CYS-THO[8 aa] | E | 6.2 /33.3 |
16 /16 |
SSR2_HUMAN Somatostatin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | F | 23.5 /29.7 |
17 /17 |
C5AR1_HUMAN C5a anaphylatoxin chemotactic receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 27.8 /33.3 |
18 /19 |
SSR2_HUMAN Somatostatin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 30.0 /33.3 |
20 /20 |
OPRD_HUMAN Delta-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI2_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | D | 41.2 /31.4 |
17 /18 |
NPY1R_HUMAN Neuropeptide Y receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAI2_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 31.6 /33.2 |
19 /20 |
OPRD_HUMAN Delta-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | PNOC_HUMAN Nociceptin[14 aa] | A | 18.2 /33.1 |
22 /22 |
OPRX_HUMAN Nociceptin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 31.6 /33.1 |
19 /19 |
OPRX_HUMAN Nociceptin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | Nanobody 6[86 aa] | A | 10.0 /33.1 |
10 /11 |
SSR2_HUMAN OPRK_HUMAN SSR2_HUMAN Somatostatin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | Somatostatin-14 (SST-14)[12 aa] | E | 18.2 /33.3 |
22 /22 |
C562_ECOLX SSR2_HUMAN Soluble cytochrome b562,Somatostatin receptor type.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | SMS_HUMAN Somatostatin-14[12 aa] | A | 15.0 /33.5 |
20 /20 |
SSR2_HUMAN Somatostatin receptor type 2,LargeBit |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | SMS_HUMAN Somatostatin-14[12 aa] | A | 10.5 /33.1 |
19 /19 |
SSR4_HUMAN Somatostatin receptor type 4 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 20.0 /33.1 |
20 /21 |
SSR4_HUMAN Somatostatin receptor type 4 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI3_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 30.8 /33.1 |
13 /13 |
SSR2_HUMAN OPRK_HUMAN SSR2_HUMAN Somatostatin receptor type 2,Kappa-type opioid rec.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | C | 33.3 /32.8 |
18 /18 |
XCR1_HUMAN A0A482LYE4_9VIRU Chemokine XC receptor 1,Non structural polyprotein.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | XCL1_HUMAN Lymphotactin[11 aa] | C | 11.1 /32.8 |
18 /22 |
XCR1_HUMAN A0A482LYE4_9VIRU Chemokine XC receptor 1,Non structural polyprotein.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | Fab heavy chain[215 aa] | C | 18.2 /32.8 |
11 /11 |
CCR8_HUMAN GFP_AEQVI C-C chemokine receptor type 8, Green fluorescent p.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | Fab light chain[215 aa] | C | 33.3 /32.8 |
3 /3 |
CCR8_HUMAN GFP_AEQVI C-C chemokine receptor type 8, Green fluorescent p.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | EP54 ligand[9 aa] | E | 26.3 /32.1 |
19 /24 |
C3AR_HUMAN C3a anaphylatoxin chemotactic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | Guanine nucleotide-binding protein G(q) subunit al.. | E | 35.3 /32.6 |
17 /17 |
C3AR_HUMAN C3a anaphylatoxin chemotactic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | Engineered G-alpha-q subunit[228 aa] | F | 44.4 /28.0 |
18 /18 |
Soluble cytochrome b562 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | engineered miniGaq[228 aa] | D | 46.2 /32.5 |
13 /13 |
LPAR6_HUMAN Lysophosphatidic acid receptor 6 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | F | 44.4 /34.4 |
18 /19 |
OPRM_HUMAN Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
I | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | G | 40.0 /34.1 |
15 /16 |
OPRM_HUMAN Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | F | 46.7 /32.5 |
15 /15 |
OPRD_HUMAN Delta-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | DA2D_PHYBI deltorphin[8 aa] | A | 31.6 /32.5 |
19 /19 |
OPRD_HUMAN Delta-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 33.3 /32.5 |
21 /21 |
OPRD_HUMAN Delta-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | CCL5_HUMAN C-C motif chemokine 5[68 aa] | A | 18.9 /33.8 |
37 /40 |
CCR5_HUMAN RUBR_CLOPA CCR5_HUMAN C-C chemokine receptor type 5,Rubredoxin chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E | CCL5_HUMAN C-C motif chemokine 5[67 aa] | C | 23.3 /32.4 |
30 /31 |
CCR5_HUMAN C-C chemokine receptor type 5 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | Q70145_9HIV1 Envelope glycoprotein gp160[398 aa] | C | 16.0 /32.4 |
25 /35 |
CCR5_HUMAN C-C chemokine receptor type 5 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | C | 41.2 /32.4 |
17 /17 |
CCR5_HUMAN C-C chemokine receptor type 5 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GALA_HUMAN Galanin[17 aa] | D | 11.8 /32.3 |
17 /18 |
GALR1_HUMAN Galanin receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | CO3_HUMAN C3a anaphylatoxin[70 aa] | E | 23.5 /32.1 |
17 /21 |
C3AR_HUMAN C3a anaphylatoxin chemotactic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | EP141 peptide agonist[10 aa] | C | 12.5 /32.1 |
16 /19 |
C3AR_HUMAN C3a anaphylatoxin chemotactic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 40.0 /31.8 |
20 /21 |
GPR17_HUMAN Uracil nucleotide/cysteinyl leukotriene receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 22.2 /31.8 |
18 /19 |
C3AR_HUMAN C3a anaphylatoxin chemotactic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | CO3_HUMAN C3a anaphylatoxin[73 aa] | A | 19.0 /31.8 |
21 /26 |
C3AR_HUMAN C3a anaphylatoxin chemotactic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | C | 33.3 /31.8 |
18 /19 |
C3AR_HUMAN C3a anaphylatoxin chemotactic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | ALA-SER-LYS-LEU-GLY-LEU-ALA-ARG[8 aa] | B | 25.0 /31.8 |
16 /19 |
C3AR_HUMAN C3a anaphylatoxin chemotactic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 36.8 /31.8 |
19 /19 |
LT4R1_HUMAN Leukotriene B4 receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI2_HUMAN GNA13_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 31.6 /26.8 |
19 /19 |
P2Y10_HUMAN Putative P2Y purinoceptor 10 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | engineered miniGa13[214 aa] | E | 40.0 /31.7 |
20 /22 |
LPAR6_HUMAN Lysophosphatidic acid receptor 6 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | D | 32.0 /31.7 |
25 /25 |
CCR8_HUMAN C-C chemokine receptor type 8,Fusion protein |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | NPY_HUMAN Neuropeptide Y[29 aa] | D | 26.1 /31.4 |
23 /28 |
NPY1R_HUMAN Neuropeptide Y receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | NPY_HUMAN C-flanking peptide of NPY[30 aa] | D | 31.6 /31.4 |
19 /22 |
NPY1R_HUMAN Neuropeptide Y receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | NMU_HUMAN Neuromedin-U-25[26 aa] | B | 14.3 /31.4 |
21 /24 |
NMUR2_HUMAN Neuromedin-U receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | B | 43.8 /31.4 |
16 /16 |
NMUR2_HUMAN Neuromedin-U receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | NMB30[10 aa] | B | 3.6 /31.3 |
28 /31 |
NMBR_HUMAN Neuromedin-B receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | G-alpha q[213 aa] | B | 40.0 /31.3 |
20 /20 |
NMBR_HUMAN Neuromedin-B receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAI2_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | B | 23.5 /35.7 |
17 /17 |
C562_ECOLX FPR2_HUMAN Soluble cytochrome b562,N-formyl peptide receptor .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | GNAI2_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 10.5 /31.3 |
19 /19 |
RL3R2_HUMAN Relaxin-3 receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | INSL5_HUMAN Insulin-like peptide INSL5 A chain[20 aa] | E | 0.0 /31.3 |
2 /2 |
RL3R2_HUMAN Relaxin-3 receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | INSL5_HUMAN Insulin-like peptide INSL5 B chain[20 aa] | E | 12.5 /31.3 |
16 /18 |
RL3R2_HUMAN Relaxin-3 receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI2_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | C | 10.0 /31.3 |
20 /20 |
RL3R2_HUMAN Relaxin-3 receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 35.0 /34.7 |
20 /21 |
OPRM_HUMAN Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 18.8 /24.4 |
16 /18 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 40.0 /31.2 |
10 /15 |
GPR34_HUMAN Probable G-protein coupled receptor 34 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 41.7 /30.7 |
12 /16 |
GPR34_HUMAN Probable G-protein coupled receptor 34 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | TAK448[11 aa] | A | 21.4 /29.0 |
28 /30 |
KISSR_HUMAN KiSS-1 receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | GNAI1_HUMAN GNAQ_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 37.0 /29.3 |
27 /27 |
KISSR_HUMAN KiSS-1 receptor,KiSS-1 receptor,KiSS-1 receptor,Ki.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN GNAQ_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | D | 24.0 /30.8 |
25 /31 |
KISSR_HUMAN KiSS-1 receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | OREX_HUMAN Orexin[10 aa] | E | 21.1 /30.7 |
19 /21 |
Q548Y0_HUMAN Hypocretin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 31.2 /30.6 |
16 /20 |
GPR34_HUMAN Probable G-protein coupled receptor 34 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | NPY_HUMAN Neuropeptide Y[22 aa] | A | 23.8 /30.5 |
21 /26 |
NPY1R_HUMAN Neuropeptide Y receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 35.7 /30.5 |
14 /14 |
NPY1R_HUMAN Neuropeptide Y receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | NMU_HUMAN Neuromedin-U-25[9 aa] | F | 20.8 /30.4 |
24 /27 |
Neuromedin-U receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | miniGsq[193 aa] | E | 35.0 /30.4 |
20 /20 |
OGR1_HUMAN Ovarian cancer G-protein coupled receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAS2_HUMAN Guanine nucleotide-binding protein G(s) subunit al.. | E | 35.3 /30.3 |
17 /18 |
Beta2 adrenergic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAS2_HUMAN Guanine nucleotide-binding protein G(s) subunit al.. | E | 27.8 /30.3 |
18 /19 |
ADRB2_HUMAN Beta-2 adrenergic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | D | 20.0 /30.3 |
20 /20 |
C5AR1_HUMAN C5a anaphylatoxin chemotactic receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | C089 peptide[6 aa] | D | 0.0 /30.3 |
16 /16 |
C5AR1_HUMAN C5a anaphylatoxin chemotactic receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI2_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 25.0 /30.2 |
16 /18 |
NPY2R_HUMAN Neuropeptide Y receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | NPY_HUMAN C-flanking peptide of NPY[31 aa] | E | 19.2 /30.2 |
26 /31 |
NPY2R_HUMAN Neuropeptide Y receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAS2_HUMAN Guanine nucleotide-binding protein G(s) subunit al.. | E | 33.3 /30.2 |
21 /24 |
ADRB2_HUMAN Beta-2 adrenergic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | Guanine nucleotide-binding protein G(q) subunit al.. | F | 33.3 /30.2 |
24 /25 |
Neuromedin-U receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | NMS_HUMAN Neuromedin-S[12 aa] | F | 15.4 /30.2 |
26 /29 |
Neuromedin-U receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 50.0 /30.1 |
10 /14 |
GPR34_HUMAN Probable G-protein coupled receptor 34 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | nanobody 7[116 aa] | A | 26.1 /30.1 |
23 /23 |
US28_HCMVA G-protein coupled receptor homolog US28 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | C5apep peptide[6 aa] | F | 15.8 /29.7 |
19 /19 |
C5AR1_HUMAN C5a anaphylatoxin chemotactic receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | MEA-LYS-PRO-ZAL-ALC-DAR[6 aa] | A | 8.3 /30.0 |
12 /12 |
C5AR1_MOUSE C5a anaphylatoxin chemotactic receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E | NPY_HUMAN Neuropeptide Y[36 aa] | A | 31.4 /33.3 |
35 /42 |
NPY1R_HUMAN Neuropeptide Y receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E | NPY_HUMAN Neuropeptide Y[36 aa] | D | 21.1 /29.9 |
19 /22 |
NPY2R_HUMAN Neuropeptide Y receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | D | 27.8 /29.9 |
18 /20 |
NPY2R_HUMAN Neuropeptide Y receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 18.2 /29.9 |
11 /14 |
NPY2R_HUMAN Neuropeptide Y receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | PYY_HUMAN Peptide YY(3-36)[25 aa] | E | 28.6 /29.9 |
21 /23 |
NPY2R_HUMAN Neuropeptide Y receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | NPY_HUMAN Neuropeptide Y[29 aa] | E | 28.0 /29.9 |
25 /28 |
NPY2R_HUMAN Neuropeptide Y receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | PMX53[7 aa] | A | 18.2 /29.9 |
22 /22 |
C562_ECOLX C5AR1_HUMAN Soluble cytochrome b562, C5a anaphylatoxin chemota.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | LYS_BPT4 Lysozyme[162 aa] | A | 50.0 /29.9 |
2 /7 |
ADRB2_HUMAN Beta-2 adrenergic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | Guanine nucleotide-binding protein G(11) subunit a.. | A | 32.1 /29.8 |
28 /28 |
P2RY1_HUMAN P2Y purinoceptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI2_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 38.1 /29.7 |
21 /21 |
P2Y12_HUMAN P2Y purinoceptor 12 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GALA_HUMAN Galanin[13 aa] | A | 9.1 /29.7 |
22 /22 |
GALR2_HUMAN Galanin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | Engineered Guanine nucleotide-binding protein G(q).. | A | 42.9 /29.7 |
21 /21 |
GALR2_HUMAN Galanin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | Engineered G protein subunit S (mini-Gs)[234 aa] | A | 17.9 /29.7 |
28 /28 |
GP174_HUMAN Probable G-protein coupled receptor 174 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | GALA_HUMAN Galanin[16 aa] | A | 5.9 /29.7 |
17 /18 |
GALR1_HUMAN Galanin receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | GALA_HUMAN Galanin[16 aa] | A | 0.0 /29.3 |
16 /17 |
GALR2_HUMAN Galanin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | spexin[14 aa] | F | 21.1 /29.7 |
19 /19 |
GALR2_HUMAN Galanin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 10.5 /29.7 |
19 /19 |
C5AR1_HUMAN C5a anaphylatoxin chemotactic receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | CO5_HUMAN C5a anaphylatoxin[74 aa] | E | 10.3 /29.7 |
29 /34 |
C5AR1_HUMAN C5a anaphylatoxin chemotactic receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | CO5_HUMAN C5a anaphylatoxin[74 aa] | A | 8.3 /29.0 |
12 /14 |
C5AR1_MOUSE C5a anaphylatoxin chemotactic receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | BM213 peptide[9 aa] | E | 10.0 /29.7 |
20 /20 |
C5AR1_HUMAN C5a anaphylatoxin chemotactic receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 19.0 /29.7 |
21 /21 |
C5AR1_HUMAN C5a anaphylatoxin chemotactic receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | CO5_MOUSE C5a anaphylatoxin[71 aa] | A | 16.7 /29.7 |
24 /26 |
C5AR1_HUMAN C5a anaphylatoxin chemotactic receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 42.9 /36.8 |
14 /14 |
CCR1_HUMAN C-C chemokine receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | B | 22.2 /33.3 |
18 /19 |
SSR2_HUMAN Somatostatin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | Nanobody6[133 aa] | A | 28.6 /32.0 |
14 /16 |
SUCR1_RAT Succinate receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | nanobody Nb71[122 aa] | A | 25.0 /29.6 |
20 /25 |
D9IEF7_BPT4 ADRB2_HUMAN ADRB2_HUMAN Endolysin, Beta-2 adrenergic receptor chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | D | 30.0 /29.6 |
10 /10 |
C562_ECOLX SUCR1_HUMAN LUCI_OPLGR Soluble cytochrome b562,Succinate receptor 1,Oplop.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 25.0 /29.5 |
12 /12 |
SUCR1_HUMAN Succinate receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 20.0 /29.5 |
10 /10 |
SUCR1_HUMAN Succinate receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | X3CL1_HUMAN Fractalkine[68 aa] | A | 20.8 /30.1 |
24 /34 |
US28_HCMVA G-protein coupled receptor homolog US28 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNA11_HUMAN Guanine nucleotide-binding protein subunit alpha-1.. | F | 37.5 /29.5 |
16 /16 |
US28_HCMVA G-protein coupled receptor homolog US28 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | F | 33.3 /29.5 |
21 /21 |
US28_HCMVA G-protein coupled receptor homolog US28 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | F | 37.5 /29.5 |
24 /24 |
US28_HCMVA G-protein coupled receptor homolog US28 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 22.7 /29.3 |
22 /23 |
GP183_HUMAN G-protein coupled receptor 183 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | kisspeptin-10[11 aa] | A | 15.4 /29.3 |
26 /28 |
KISSR_HUMAN KiSS-1 receptor,KiSS-1 receptor,KiSS-1 receptor,Ki.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | Camelid Antibody Fragment[120 aa] | A | 31.2 /29.3 |
16 /19 |
LYS_BPT4 ADRB2_HUMAN ADRB2_HUMAN Lysozyme, Beta-2 adrenergic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 25.0 /34.3 |
20 /20 |
FPR2_HUMAN N-formyl peptide receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 28.6 /35.7 |
21 /21 |
FPR1_HUMAN fMet-Leu-Phe receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 47.1 /28.4 |
17 /17 |
PAR1_HUMAN Proteinase-activated receptor 1 LgBiT |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 29.4 /29.2 |
17 /17 |
PTAFR_HUMAN Platelet-activating factor receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E | BA1[9 aa] | D | 29.0 /29.2 |
31 /31 |
BRS3_HUMAN Bombesin receptor subtype-3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | Synthetic nanobody 51 (Sb51)[111 aa] | E | 5.6 /29.1 |
18 /20 |
Q548Y0_HUMAN Hypocretin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E | GNAQ_HUMAN Guanine nucleotide-binding protein G(q) subunit al.. | A | 31.0 /28.7 |
29 /32 |
KISSR_HUMAN KiSS-1 receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | KISS1_HUMAN Metastin[9 aa] | A | 22.2 /29.0 |
18 /21 |
KISSR_HUMAN KiSS-1 receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E | MCH_HUMAN Pro-MCH[17 aa] | F | 26.1 /28.6 |
23 /23 |
MCHR1_HUMAN Melanin-concentrating hormone receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | MCH_HUMAN Melanin-concentrating hormone[17 aa] | E | 24.2 /28.9 |
33 /33 |
MCHR1_HUMAN Fusion protein 1,Melanin-concentrating hormone rec.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 24.0 /28.9 |
25 /27 |
MCHR1_HUMAN Fusion protein 1,Melanin-concentrating hormone rec.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | Engineered G-alpha-q[240 aa] | A | 40.9 /28.7 |
22 /22 |
GHSR_HUMAN Growth hormone secretagogue receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | TAK448[11 aa] | A | 25.8 /28.7 |
31 /35 |
KISSR_HUMAN KiSS-1 receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | MCH_HUMAN Pro-MCH[15 aa] | F | 18.5 /28.7 |
27 /27 |
MCHR2_HUMAN Melanin-concentrating hormone receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 10.0 /24.3 |
20 /20 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2,hydroxycarboxyli.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | F | 20.0 /28.6 |
20 /21 |
MCHR1_HUMAN Melanin-concentrating hormone receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | Engineered Guanine nucleotide-binding protein subu.. | E | 46.7 /30.7 |
15 /16 |
Q548Y0_HUMAN Hypocretin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | Guanine nucleotide-binding protein G(q) subunit al.. | A | 45.0 /29.3 |
20 /20 |
GALR2_HUMAN Galanin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | Guanine nucleotide-binding protein G(q)[226 aa] | F | 47.6 /29.7 |
21 /21 |
GALR2_HUMAN Galanin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | Engineered Guanine nucleotide-binding protein G(q).. | E | 38.5 /34.4 |
13 /13 |
SSR2_HUMAN Somatostatin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAS2_HUMAN GNAS2_HUMAN Guanine nucleotide-binding protein G(s) subunit al.. | E | 20.0 /29.5 |
35 /35 |
GP174_HUMAN Probable G-protein coupled receptor 174 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAS2_HUMAN Guanine nucleotide-binding protein G(s) subunit al.. | D | 31.6 /29.5 |
19 /19 |
C562_ECOLX SUCR1_HUMAN Soluble cytochrome b562,Succinate receptor 1,Oplop.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAS complex locus[239 aa] | E | 31.0 /29.8 |
29 /29 |
C562_ECOLX P2RY1_HUMAN Soluble cytochrome b562,P2Y purinoceptor 1,Soluble.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAS2_HUMAN GNAS2_HUMAN Guanine nucleotide-binding protein G(s) subunit al.. | D | 38.5 /28.0 |
26 /26 |
C562_ECOLX E7FEL0_DANRE Soluble cytochrome b562,G-protein coupled receptor.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GHRL_HUMAN Ghrelin-28[15 aa] | F | 21.4 /28.0 |
14 /17 |
Soluble cytochrome b562 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | G subunit q (Gi1-Gq chimeric)[234 aa] | E | 36.0 /27.9 |
25 /25 |
PAR1_HUMAN Proteinase-activated receptor 1 LgBiT |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 37.5 /27.3 |
16 /18 |
GHSR_HUMAN Growth hormone secretagogue receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | GHRL_HUMAN Appetite-regulating hormone[16 aa] | B | 18.2 /27.9 |
22 /26 |
GHSR_HUMAN Growth hormone secretagogue receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 23.5 /27.2 |
17 /20 |
PD2R2_HUMAN Prostaglandin D2 receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 23.1 /24.5 |
13 /16 |
C562_ECOLX HCAR2_HUMAN Soluble cytochrome b562,Hydroxycarboxylic acid rec.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | GHRL_HUMAN Ghrelin-27[12 aa] | E | 18.2 /27.3 |
22 /25 |
GHSR_HUMAN Growth hormone secretagogue receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | Fab7881 Heavy Chain[218 aa] | A | 0.0 /27.0 |
8 /10 |
C562_ECOLX GHSR_HUMAN Chimera of Soluble cytochrome b562 and Growth horm.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | Fab7881 Light Chain[219 aa] | A | 0.0 /27.0 |
2 /2 |
C562_ECOLX GHSR_HUMAN Chimera of Soluble cytochrome b562 and Growth horm.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | 3SI1A_DENAN Toxin AdTx1[65 aa] | B | 18.2 /26.6 |
22 /22 |
ADA1A_HUMAN Alpha-1A adrenergic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | Guanine nucleotide-binding protein G(s) subunit al.. | F | 34.6 /26.0 |
26 /26 |
GPR4_MOUSE G-protein coupled receptor 4 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | Guanine nucleotide-binding protein G(s) subunit al.. | E | 34.6 /26.0 |
26 /26 |
GPR4_MOUSE G-protein coupled receptor 4 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | C | 16.7 /25.6 |
18 /20 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | D | 26.3 /33.3 |
19 /19 |
SSR2_HUMAN Somatostatin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 15.4 /25.6 |
13 /14 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 18.8 /25.6 |
16 /16 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 20.0 /25.6 |
15 /16 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 19.0 /25.5 |
21 /21 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 21.4 /25.3 |
14 /16 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 20.0 /24.5 |
15 /16 |
HCAR2_HUMAN Hydroxy-carboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 18.8 /24.5 |
16 /18 |
HCAR2_HUMAN Human hydroxycarboxylic acid receptor 2,Hydroxycar.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | A | 14.3 /24.5 |
14 /15 |
HCAR2_HUMAN Human hydroxycarboxylic acid receptor 2,Hydroxycar.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | F | 0.0 /36.5 |
1 /1 |
CXCR2_HUMAN C-X-C chemokine receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | A | 0.0 /34.3 |
2 /2 |
FPR2_HUMAN N-formyl peptide receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | GBB1_RAT Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | A | 0.0 /34.4 |
1 /1 |
BKRB1_HUMAN B1 bradykinin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | A | 0.0 /35.9 |
1 /1 |
FPR1_HUMAN fMet-Leu-Phe receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | A | 0.0 /34.6 |
1 /1 |
CCL5_HUMAN CCR5_HUMAN C-C motif chemokine 5,C-C chemokine receptor type .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | A | 0.0 /34.4 |
1 /1 |
Bradykinin receptor BK2R |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | F | 0.0 /28.0 |
1 /1 |
Soluble cytochrome b562 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | F | 0.0 /29.5 |
2 /2 |
US28_HCMVA G-protein coupled receptor homolog US28 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | D | 100.0 /35.1 |
1 /1 |
C562_ECOLX OPRM_MOUSE Soluble cytochrome b562,Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GBB1_RAT Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | E | 0.0 /34.3 |
2 /2 |
FPR2_HUMAN N-formyl peptide receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GBB1_RAT Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | E | 0.0 /35.7 |
1 /1 |
FPR1_HUMAN fMet-Leu-Phe receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | A | 0.0 /31.8 |
1 /1 |
LT4R1_HUMAN Leukotriene B4 receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | D | 50.0 /35.6 |
2 /2 |
C562_ECOLX APJ_HUMAN Soluble cytochrome b562,Apelin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | F | 0.0 /30.4 |
1 /1 |
Neuromedin-U receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | E | 100.0 /33.3 |
2 /2 |
C562_ECOLX SSR2_HUMAN Soluble cytochrome b562,Somatostatin receptor type.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | GBB1_RAT Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | A | 0.0 /29.7 |
1 /1 |
GALR2_HUMAN Galanin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | B | 0.0 /34.6 |
1 /1 |
C562_ECOLX FPR2_HUMAN Soluble cytochrome b562,N-formyl peptide receptor .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | D | 0.0 /29.9 |
1 /1 |
NPY2R_HUMAN Neuropeptide Y receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GBB1_BOVIN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | A | 100.0 /34.1 |
1 /1 |
SSR2_HUMAN Somatostatin receptor type 2,LargeBit |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | A | 0.0 /29.3 |
1 /1 |
GALR2_HUMAN Galanin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | D | 0.0 /35.6 |
1 /1 |
CX3C1_HUMAN CX3C chemokine receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | D | 0.0 /35.1 |
1 /1 |
X3CL1_HUMAN CX3C1_HUMAN Processed fractalkine,CX3C chemokine receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | A | 0.0 /29.7 |
1 /1 |
GP174_HUMAN Probable G-protein coupled receptor 174 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | A | 100.0 /29.8 |
1 /1 |
P2RY1_HUMAN P2Y purinoceptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | E | 0.0 /31.8 |
1 /1 |
GPR17_HUMAN Uracil nucleotide/cysteinyl leukotriene receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | E | 0.0 /29.9 |
1 /1 |
NPY2R_HUMAN Neuropeptide Y receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | A | 100.0 /24.5 |
1 /1 |
HCAR2_HUMAN Hydroxy-carboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | E | 0.0 /32.1 |
1 /1 |
C3AR_HUMAN C3a anaphylatoxin chemotactic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | E | 0.0 /30.7 |
1 /1 |
GPR34_HUMAN Probable G-protein coupled receptor 34 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | E | 0.0 /29.5 |
1 /1 |
GP174_HUMAN Probable G-protein coupled receptor 174 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | E | 100.0 /24.4 |
1 /1 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | A | 0.0 /38.5 |
1 /1 |
CML2_HUMAN Chemerin-like receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | E | 100.0 /25.6 |
1 /1 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | A | 50.0 /37.5 |
2 /3 |
CXCR4_HUMAN C-X-C chemokine receptor type 4 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | D | 100.0 /31.7 |
1 /2 |
CCR8_HUMAN C-C chemokine receptor type 8,Fusion protein |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | A | 0.0 /30.1 |
1 /1 |
GPR34_HUMAN Probable G-protein coupled receptor 34 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | E | 0.0 /29.8 |
1 /1 |
C562_ECOLX P2RY1_HUMAN Soluble cytochrome b562,P2Y purinoceptor 1,Soluble.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | E | 100.0 /28.9 |
1 /1 |
MCHR1_HUMAN Fusion protein 1,Melanin-concentrating hormone rec.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GBB1_RAT Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | E | 0.0 /30.6 |
1 /1 |
GPR34_HUMAN Probable G-protein coupled receptor 34 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | A | 100.0 /35.7 |
1 /1 |
SSR1_HUMAN Somatostatin receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | A | 0.0 /33.5 |
2 /2 |
SSR3_HUMAN Somatostatin receptor type 3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | C | 0.0 /36.5 |
1 /1 |
CXCR2_HUMAN C-X-C chemokine receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | A | 0.0 /29.2 |
1 /1 |
PTAFR_HUMAN Platelet-activating factor receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | D | 0.0 /29.2 |
2 /2 |
BRS3_HUMAN Bombesin receptor subtype-3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | D | 0.0 /35.6 |
1 /1 |
C562_ECOLX APJ_HUMAN Soluble cytochrome b562,Apelin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | GBB1_HUMAN Guanine nucleotide-binding protein G(I)/G(S)/G(T) .. | C | 50.0 /32.8 |
2 /2 |
XCR1_HUMAN A0A482LYE4_9VIRU Chemokine XC receptor 1,Non structural polyprotein.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit al.. | E | 19.0 /24.4 |
21 /21 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
3.a3:asym_id for the contact molecule. 4.a4:asym_id for the template homologue. 5.identity[%]5:sequence identity between the query and the template homologue only for the contact residues. Number after the slash / is sequence identity for all the aligned region. 6.Ncon6:number of aligned contact residues for the query. Number after the slash / is number of contact residues in the template homologue. | |||||||
![]() |
|||||||
359 | pdb_id | contact mol | homologue | ||||
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
a3 | description | a4 | identity[%]5 | Ncon6 | description | |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B |
ZD7
|
A | 100.0 /99.7 |
14 /14 |
C562_ECOLX AGTR1_HUMAN Soluble cytochrome b562,Type-1 angiotensin II rece.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
I |
NAG
|
A | 100.0 /98.7 |
2 /2 |
AGTR1_HUMAN C562_ECOLX AGTR1_HUMAN Type-1 angiotensin II receptor,Soluble cytochrome .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
NAG
|
A | 100.0 /99.4 |
3 /3 |
Angiotensin receptor AT1R |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
Y01
|
A | 30.0 /29.7 |
10 /10 |
P2RY1_HUMAN RUBR_CLOPA P2RY1_HUMAN P2Y purinoceptor 1, Rubredoxin, P2Y purinoceptor 1.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
Y01
|
A | 16.7 /29.7 |
12 /12 |
P2RY1_HUMAN RUBR_CLOPA P2RY1_HUMAN P2Y purinoceptor 1, Rubredoxin, P2Y purinoceptor 1.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
Y01
|
A | 20.0 /29.7 |
10 /10 |
P2RY1_HUMAN RUBR_CLOPA P2RY1_HUMAN P2Y purinoceptor 1, Rubredoxin, P2Y purinoceptor 1.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
Y01
|
A | 42.9 /31.8 |
7 /7 |
LT4R1_HUMAN Leukotriene B4 receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
Y01
|
A | 50.0 /31.8 |
2 /3 |
LT4R1_HUMAN Leukotriene B4 receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
I |
Y01
|
A | 20.0 /31.8 |
5 /5 |
LT4R1_HUMAN Leukotriene B4 receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
J |
Y01
|
A | 14.3 /31.8 |
7 /7 |
LT4R1_HUMAN Leukotriene B4 receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
Y01
|
A | 100.0 /94.7 |
8 /8 |
AGTR1_HUMAN C562_ECOLX AGTR1_HUMAN AT118-H nanobody, Type-1 angiotensin II receptor, .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
Y01
|
A | 42.9 /30.5 |
14 /14 |
OGR1_HUMAN Ovarian cancer G-protein coupled receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
Y01
|
A | 100.0 /94.3 |
7 /7 |
AGTR1_HUMAN C562_ECOLX AGTR1_HUMAN Nanobody AT206,Type-1 angiotensin II receptor,Solu.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
LSN
|
A | 100.0 /94.5 |
13 /15 |
AGTR1_HUMAN C562_ECOLX AGTR1_HUMAN Type-1 angiotensin II receptor Soluble cytochrome .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
LSN
|
A | 100.0 /94.3 |
13 /15 |
AGTR1_HUMAN C562_ECOLX AGTR1_HUMAN Nanobody AT206,Type-1 angiotensin II receptor,Solu.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B |
OLM
|
A | 100.0 /99.6 |
13 /13 |
C562_ECOLX AGTR1_HUMAN AGTR1_HUMAN Chimera protein of Soluble cytochrome b562 and Typ.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
OLM
|
A | 100.0 /94.2 |
14 /16 |
AGTR1_HUMAN C562_ECOLX AGTR1_HUMAN Nanobody AT209,Type-1 angiotensin II receptor,Solu.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B |
KNT
|
A | 33.3 /40.0 |
6 /21 |
CLTR1_HUMAN C562_ECOLX CLTR1_HUMAN Cysteinyl leukotriene receptor 1,Soluble cytochrom.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
ZLK
|
A | 50.0 /38.5 |
8 /18 |
CLTR1_HUMAN C562_ECOLX CLTR1_HUMAN Cysteinyl leukotriene receptor 1,Soluble cytochrom.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
8EM
|
A | 39.1 /38.6 |
23 /23 |
C562_ECOLX AGTR2_HUMAN Soluble cytochrome b562,Type-2 angiotensin II rece.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
VFD
|
A | 52.9 /38.5 |
17 /17 |
C562_ECOLX AGTR2_HUMAN Soluble cytochrome b562,Type-2 angiotensin II rece.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
K |
HEZ
|
A | 0.0 /38.5 |
1 /5 |
C562_ECOLX AGTR2_HUMAN Soluble cytochrome b562,Type-2 angiotensin II rece.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B |
KO5
|
A | 28.6 /38.4 |
14 /19 |
CLTR2_HUMAN C562_ECOLX CLTR2_HUMAN Cysteinyl leukotriene receptor 2,Soluble cytochrom.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
ITD
|
A | 25.0 /36.2 |
12 /12 |
CXCR4_HUMAN LYS_BPT4 CXCR4_HUMAN C-X-C chemokine receptor type 4, Lysozyme Chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
8ES
|
A | 45.0 /37.6 |
20 /20 |
C562_ECOLX AGTR2_HUMAN Chimera protein of Type-2 angiotensin II receptor .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B |
KNW
|
A | 23.5 /37.7 |
17 /22 |
CLTR2_HUMAN C562_ECOLX CLTR2_HUMAN Cysteinyl leukotriene receptor 2,Soluble cytochrom.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
IVB
|
A | 21.1 /37.3 |
19 /19 |
OPRK_HUMAN Kappa-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
CVV
|
A | 33.3 /36.9 |
15 /15 |
C562_ECOLX OPRK_HUMAN Soluble cytochrome b562, kappa-type opioid recepto.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B |
KNZ
|
A | 26.1 /37.1 |
23 /26 |
CLTR2_HUMAN C562_ECOLX CLTR2_HUMAN Cysteinyl leukotriene receptor 2,Soluble cytochrom.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B |
A1LW1
|
A | 17.6 /37.0 |
17 /20 |
CXCR3_HUMAN C-X-C chemokine receptor type 3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B |
A1LW2
|
A | 33.3 /37.0 |
9 /9 |
CXCR3_HUMAN C-X-C chemokine receptor type 3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
4IE
|
D | 33.3 /36.9 |
9 /10 |
C562_ECOLX CXCR3_HUMAN LUCI_OPLGR Soluble cytochrome b562,C-X-C chemokine receptor t.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
JLW
|
A | 44.4 /36.7 |
9 /16 |
CCR7_HUMAN NANA_STREE CCR7_HUMAN C-C chemokine receptor type 7,Sialidase A,C-C chem.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
TAR
|
A | 100.0 /36.7 |
1 /4 |
CCR7_HUMAN NANA_STREE CCR7_HUMAN C-C chemokine receptor type 7,Sialidase A,C-C chem.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
VH6
|
D | 30.0 /38.2 |
10 /10 |
CXCR4_HUMAN C-X-C chemokine receptor type 4 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
VH6
|
A | 27.3 /36.6 |
11 /11 |
C562_ECOLX CXCR4_HUMAN CXCR4_HUMAN Soluble cytochrome b562,C-X-C chemokine receptor t.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
K |
D21
|
C | 20.0 /36.5 |
5 /5 |
CXCR4_HUMAN C-X-C chemokine receptor type 4 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
N |
D21
|
C | 25.0 /36.5 |
4 /4 |
CXCR4_HUMAN C-X-C chemokine receptor type 4 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
A1D8K
|
B | 31.2 /36.6 |
16 /16 |
C562_ECOLX CXCR4_HUMAN CXCR4_HUMAN Soluble cytochrome b562,C-X-C chemokine receptor t.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
A1D8L
|
A | 27.3 /36.6 |
11 /11 |
C562_ECOLX CXCR4_HUMAN CXCR4_HUMAN Soluble cytochrome b562,C-X-C chemokine receptor t.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
A1LVW
|
E | 44.4 /36.6 |
9 /9 |
GPER1_HUMAN G-protein coupled estrogen receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B |
BF0
|
A | 0.0 /36.5 |
6 /14 |
OPRM_MOUSE LYS_BPT4 OPRM_MOUSE Mu-type opioid receptor, lysozyme chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
43I
|
B | 33.3 /36.4 |
9 /9 |
C562_ECOLX CXCR3_HUMAN OPRK_HUMAN CXCR3_HUMAN Soluble cytochrome b562,C-X-C chemokine receptor t.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B |
VPX
|
A | 40.0 /36.4 |
5 /21 |
PAR1_HUMAN LYS_BPT4 PAR1_HUMAN Proteinase-activated receptor 1, Lysozyme |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B |
VRJ
|
A | 18.2 /36.4 |
11 /18 |
LT4R1_HUMAN FLAV_DESVH LT4R1_HUMAN Leukotriene B4 receptor 1,Flavodoxin,Leukotriene B.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
I |
2PE
|
A | 45.5 /36.4 |
11 /12 |
LT4R1_HUMAN FLAV_DESVH LT4R1_HUMAN Leukotriene B4 receptor 1,Flavodoxin,Leukotriene B.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
A1BNM
|
A | 27.3 /34.3 |
11 /11 |
OPRM_HUMAN Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
A1BNM
|
A | 26.7 /36.4 |
15 /15 |
Kappa-Opioid Receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
LPC
|
B | 25.0 /36.2 |
8 /8 |
C562_ECOLX CXCR3_HUMAN OPRK_HUMAN CXCR3_HUMAN Soluble cytochrome b562,C-X-C chemokine receptor t.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
FI6
|
B | 50.0 /36.2 |
8 /9 |
C562_ECOLX CXCR3_HUMAN OPRK_HUMAN CXCR3_HUMAN Soluble cytochrome b562,C-X-C chemokine receptor t.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
F7N
|
A | 21.4 /36.7 |
14 /17 |
CCR2_HUMAN RUBR_CLOPA CCR2_HUMAN C-C chemokine receptor type 2,Rubredoxin,C-C chemo.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
O |
F7N
|
A | 21.4 /36.8 |
14 /16 |
CCR2_HUMAN RUBR_CLOPA CCR2_HUMAN C-C chemokine receptor type 2,Rubredoxin,C-C chemo.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B |
73R
|
A | 23.1 /35.9 |
13 /15 |
CCR2_HUMAN D9IEF7_BPT4 CCR2_HUMAN Chimera protein of CC chemokine receptor type 2 is.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
VT5
|
A | 64.3 /35.9 |
14 /14 |
CCR2_HUMAN D9IEF7_BPT4 CCR2_HUMAN Chimera protein of CC chemokine receptor type 2 is.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
A1D5D
|
A | 12.5 /35.7 |
16 /16 |
SSR1_HUMAN Somatostatin receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
GJ9
|
A | 33.3 /37.0 |
15 /15 |
ACKR3_HUMAN Atypical chemokine receptor 3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
8EH
|
A | 31.2 /37.9 |
16 /16 |
APJ_HUMAN RUBR_CLOPA APJ_HUMAN Apelin receptor, with Rubredoxin insertion |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
8EH
|
D | 46.2 /35.6 |
13 /13 |
C562_ECOLX APJ_HUMAN Soluble cytochrome b562,Apelin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B |
A1D5N
|
A | 62.5 /40.7 |
8 /16 |
APJ_HUMAN A7ZVB5_ECO24 APJ_HUMAN Apelin receptor,Soluble cytochrome b562 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
A1D5N
|
A | 37.5 /35.6 |
16 /16 |
APJ_HUMAN Apelin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
8RI
|
C | 20.0 /35.4 |
10 /10 |
OPRM_MOUSE Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
KZR
|
C | 40.0 /35.4 |
15 /16 |
OPRM_MOUSE Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
L0X
|
D | 29.4 /35.4 |
17 /18 |
OPRM_MOUSE Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
A1AQ2
|
C | 22.2 /35.4 |
9 /9 |
OPRM_MOUSE Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
EID
|
E | 30.8 /35.3 |
13 /13 |
OPRM_MOUSE Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
JDC
|
A | 33.3 /39.0 |
15 /20 |
OPRK_HUMAN LYS_BPT4 OPRK_HUMAN Kappa-type opioid receptor, Lysozyme |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
JDC
|
A | 38.5 /36.0 |
13 /13 |
OPRK_HUMAN Kappa opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
JDC
|
A | 17.6 /35.3 |
17 /17 |
OPRK_HUMAN Kappa-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
A1AD6
|
A | 21.4 /35.3 |
14 /14 |
OPRK_HUMAN Kappa-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
A1AD5
|
A | 18.2 /35.3 |
11 /11 |
OPRK_HUMAN Kappa-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
LTD
|
E | 7.7 /35.2 |
13 /15 |
CLTR2_HUMAN Cysteinyl leukotriene receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
U9I
|
A | 27.3 /35.6 |
11 /11 |
OPRK_HUMAN Kappa-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
U9I
|
A | 21.4 /35.2 |
14 /14 |
OPRK_HUMAN Kappa-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
4AI
|
D | 20.0 /35.2 |
15 /15 |
C562_ECOLX CXCR3_HUMAN LUCI_OPLGR Soluble cytochrome b562,C-X-C chemokine receptor t.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
U99
|
A | 27.8 /35.2 |
18 /18 |
OPRK_HUMAN Kappa-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
EIG
|
D | 30.8 /35.1 |
13 /13 |
C562_ECOLX OPRM_MOUSE Soluble cytochrome b562,Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
NG0
|
A | 30.0 /35.0 |
10 /10 |
OPRM_MOUSE Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
I |
VF1
|
A | 16.7 /34.9 |
12 /14 |
OPRM_MOUSE Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
A4R
|
A | 38.5 /34.8 |
13 /13 |
CCR5_HUMAN RUBR_CLOPA CCR5_HUMAN C-C chemokine receptor type 5,Rubredoxin,C-C chemo.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
A1APV
|
B | 33.3 /34.8 |
9 /9 |
OPRM_MOUSE Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
A1APU
|
B | 50.0 /34.8 |
14 /14 |
OPRM_MOUSE Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
GI9
|
A | 26.1 /34.6 |
23 /23 |
SSR2_HUMAN XYNA_NIACI SSR2_HUMAN Somatostatin receptor type 2,Endo-1,4-beta-xylanas.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
0NN
|
A | 25.0 /33.6 |
16 /16 |
C562_ECOLX OPRX_HUMAN Fusion protein of Nociceptin receptor and cytochro.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
DGV
|
A | 28.6 /33.6 |
14 /14 |
C562_ECOLX OPRX_HUMAN Soluble cytochrome b562,Nociceptin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
16C
|
E | 25.0 /34.6 |
4 /5 |
FPR2_HUMAN N-formyl peptide receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
A1LXR
|
A | 16.7 /34.6 |
6 /7 |
FPR2_HUMAN N-formyl peptide receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
8QY
|
E | 18.2 /35.3 |
11 /11 |
C562_ECOLX OPRM_MOUSE Soluble cytochrome b562, Mu-type opioid receptor c.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
8QY
|
A | 16.7 /34.4 |
12 /12 |
OPRM_HUMAN Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
7V7
|
A | 41.7 /34.4 |
12 /13 |
OPRM_HUMAN Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
MOI
|
A | 0.0 /34.4 |
6 /6 |
OPRM_HUMAN Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
WH9
|
A | 25.0 /34.4 |
12 /12 |
OPRM_HUMAN Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
FUI
|
E | 41.7 /34.3 |
12 /13 |
FPR2_HUMAN N-formyl peptide receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
I8B
|
A | 13.3 /34.2 |
15 /15 |
SSR4_HUMAN Somatostatin receptor type 4 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
VV9
|
A | 11.1 /34.2 |
9 /9 |
OPRM_HUMAN Soluble cytochrome b562,Mu-type opioid receptor,Mu.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
18C
|
A | 0.0 /34.1 |
6 /7 |
FPR2_HUMAN N-formyl peptide receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
79K
|
A | 40.0 /34.8 |
20 /20 |
CCR9_HUMAN C-C chemokine receptor type 9 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
WH2
|
A | 28.6 /34.1 |
14 /15 |
OPRM_HUMAN Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
L |
LMN
|
A | 40.0 /34.0 |
5 /5 |
ACKR3_HUMAN Atypical chemokine receptor 3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
MRV
|
A | 36.8 /34.0 |
19 /19 |
CCR5_HUMAN RUBR_CLOPA CCR5_HUMAN Chimera protein of C-C chemokine receptor type 5 a.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
A4X
|
A | 31.6 /33.9 |
19 /19 |
CCR5_HUMAN RUBR_CLOPA CCR5_HUMAN C-C chemokine receptor type 5,Rubredoxin,C-C chemo.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
DGW
|
A | 25.0 /33.8 |
16 /16 |
C562_ECOLX OPRX_HUMAN Soluble cytochrome b562,Nociceptin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B |
8TZ
|
A | 33.3 /33.8 |
12 /14 |
D9IEF7_BPT4 PAR2_HUMAN C562_ECOLX PAR2_HUMAN Lysozyme,Proteinase-activated receptor 2,Soluble c.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B |
8UN
|
A | 30.0 /33.8 |
10 /10 |
D9IEF7_BPT4 PAR2_HUMAN C562_ECOLX PAR2_HUMAN Lysozyme,Proteinase-activated receptor 2,Soluble c.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B |
EJ4
|
A | 0.0 /35.0 |
5 /12 |
OPRD_MOUSE LYS_BPT4 OPRD_MOUSE Delta-type opioid receptor, Lysozyme chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
T |
EJ4
|
A | 23.1 /33.3 |
13 /13 |
C562_ECOLX OPRD_HUMAN Soluble cytochrome b562, Delta-type opioid recepto.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B |
EBX
|
A | 50.0 /38.0 |
18 /18 |
CXCR2_HUMAN Q9V2J8_PYRAB CXCR2_HUMAN C-X-C chemokine receptor type 2,GlgA glycogen synt.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
EBX
|
A | 60.0 /33.3 |
17 /18 |
Human CCR6 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
IUD
|
D | 23.1 /33.3 |
13 /13 |
SSR2_HUMAN Somatostatin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
A1AWC
|
A | 40.0 /33.3 |
15 /15 |
OPRD_HUMAN Delta-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
A1A1W
|
A | 14.3 /33.3 |
14 /14 |
Human CCR6 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
A1A2A
|
A | 6.7 /33.3 |
15 /15 |
CCR6, Soluble cytochrome b562 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
A1LXY
|
A | 25.0 /33.2 |
8 /8 |
OPRD_HUMAN Delta-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
A1AWD
|
A | 33.3 /33.2 |
15 /15 |
OPRD_HUMAN Delta-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B |
6AT
|
A | 35.3 /33.2 |
17 /25 |
P2Y12_HUMAN C562_ECOLX P2Y12_HUMAN P2Y purinoceptor 12, Soluble cytochrome b562 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
9FI
|
A | 22.2 /32.8 |
9 /9 |
SSR2_HUMAN Somatostatin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
OWY
|
A | 22.2 /32.5 |
18 /18 |
Delta opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
A1LYV
|
E | 15.4 /32.4 |
13 /13 |
SUCR1_HUMAN Succinate receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B |
9ER
|
A | 23.5 /32.4 |
17 /17 |
PTAFR_HUMAN FLAV_DESVH PTAFR_HUMAN Platelet-activating factor receptor,Flavodoxin,Pla.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
N |
H95
|
A | 16.7 /32.0 |
6 /6 |
SUCR1_RAT Succinate receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B |
9AO
|
A | 16.7 /31.9 |
18 /20 |
NPY1R_HUMAN A0A097J792_BPT4 Neuropeptide Y receptor type 1,T4 Lysozyme |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
LTB
|
A | 30.8 /31.8 |
13 /13 |
LT4R1_HUMAN Leukotriene B4 receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
K |
8IO
|
A | 33.3 /31.8 |
15 /15 |
LT4R1_HUMAN Leukotriene B4 receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
CLR
|
A | 37.5 /33.2 |
8 /8 |
P2Y12_HUMAN C562_ECOLX P2Y12_HUMAN P2Y purinoceptor 12, Soluble cytochrome b562 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
CLR
|
A | 16.7 /29.7 |
6 /6 |
P2RY1_HUMAN RUBR_CLOPA P2RY1_HUMAN P2Y purinoceptor 1, Rubredoxin, P2Y purinoceptor 1.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
CLR
|
A | 42.9 /36.9 |
7 /7 |
C562_ECOLX OPRK_HUMAN Soluble cytochrome b562, kappa-type opioid recepto.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
CLR
|
A | 33.3 /35.3 |
3 /3 |
C562_ECOLX FPR2_HUMAN Soluble cytochrome b562,N-formyl peptide receptor .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
CLR
|
A | 50.0 /32.5 |
6 /6 |
Delta opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
CLR
|
A | 100.0 /99.4 |
11 /11 |
Angiotensin receptor AT1R |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
CLR
|
A | 100.0 /99.4 |
9 /9 |
Angiotensin receptor AT1R |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
I |
CLR
|
A | 100.0 /99.4 |
7 /7 |
Angiotensin receptor AT1R |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
J |
CLR
|
A | 100.0 /99.4 |
9 /9 |
Angiotensin receptor AT1R |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
K |
CLR
|
A | 100.0 /99.4 |
7 /7 |
Angiotensin receptor AT1R |
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
L |
CLR
|
A | 100.0 /99.4 |
2 /2 |
Angiotensin receptor AT1R |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
CLR
|
A | 37.5 /34.4 |
8 /8 |
Bradykinin receptor BK2R |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
CLR
|
A | 25.0 /34.4 |
4 /5 |
Bradykinin receptor BK2R |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
CLR
|
A | 20.0 /34.4 |
10 /10 |
Bradykinin receptor BK2R |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
I |
CLR
|
F | 22.2 /28.0 |
9 /9 |
Soluble cytochrome b562 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
CLR
|
A | 0.0 /34.0 |
3 /3 |
ACKR3_HUMAN Atypical chemokine receptor 3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
CLR
|
D | 33.3 /35.1 |
9 /9 |
C562_ECOLX OPRM_MOUSE Soluble cytochrome b562,Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
CLR
|
D | 40.0 /35.1 |
10 /10 |
C562_ECOLX OPRM_MOUSE Soluble cytochrome b562,Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
CLR
|
A | 50.0 /29.7 |
4 /4 |
GALR1_HUMAN Galanin receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
CLR
|
A | 33.3 /29.7 |
3 /4 |
GALR2_HUMAN Galanin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
CLR
|
D | 0.0 /34.7 |
1 /1 |
SSR2_HUMAN Somatostatin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
CLR
|
E | 0.0 /33.3 |
3 /3 |
SSR2_HUMAN Somatostatin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
CLR
|
A | 14.3 /35.3 |
7 /7 |
OPRK_HUMAN Kappa-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
I |
CLR
|
A | 33.3 /35.3 |
3 /3 |
OPRK_HUMAN Kappa-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
CLR
|
A | 33.3 /31.8 |
6 /6 |
C3AR_HUMAN C3a anaphylatoxin chemotactic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
CLR
|
A | 25.0 /31.8 |
4 /4 |
C3AR_HUMAN C3a anaphylatoxin chemotactic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
I |
CLR
|
A | 25.0 /31.8 |
4 /4 |
C3AR_HUMAN C3a anaphylatoxin chemotactic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
J |
CLR
|
A | 40.0 /31.8 |
5 /5 |
C3AR_HUMAN C3a anaphylatoxin chemotactic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
K |
CLR
|
A | 14.3 /31.8 |
7 /7 |
C3AR_HUMAN C3a anaphylatoxin chemotactic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
I |
CLR
|
E | 37.5 /29.5 |
8 /8 |
GP174_HUMAN Probable G-protein coupled receptor 174 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
BA |
CLR
|
C | 100.0 /36.6 |
1 /1 |
CXCR4_HUMAN C-X-C chemokine receptor type 4 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
Q |
CLR
|
C | 80.0 /36.6 |
5 /5 |
CXCR4_HUMAN C-X-C chemokine receptor type 4 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
CLR
|
A | 25.0 /36.9 |
4 /4 |
CXCR4_HUMAN C-X-C chemokine receptor type 4 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
CLR
|
B | 20.0 /36.6 |
5 /5 |
C562_ECOLX CXCR4_HUMAN CXCR4_HUMAN Soluble cytochrome b562,C-X-C chemokine receptor t.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
CLR
|
E | 0.0 /37.1 |
1 /1 |
ACKR3_HUMAN Atypical chemokine receptor 3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
CLR
|
D | 40.0 /32.5 |
5 /5 |
LPAR6_HUMAN Lysophosphatidic acid receptor 6 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
NKP
|
D | 12.5 /32.5 |
16 /16 |
LPAR6_HUMAN Lysophosphatidic acid receptor 6 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
KKF
|
D | 22.2 /31.7 |
9 /14 |
GP183_HUMAN GP183_HUMAN G-protein coupled receptor 183,Soluble cytochrome .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
OS9
|
D | 26.7 /31.7 |
15 /15 |
CCR8_HUMAN C-C chemokine receptor type 8,Fusion protein |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
OXF
|
D | 33.3 /31.7 |
12 /12 |
CCR8_HUMAN C-C chemokine receptor type 8,Fusion protein |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
IYF
|
C | 11.1 /31.3 |
9 /9 |
RL3R2_HUMAN Relaxin-3 receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
IYM
|
C | 15.4 /31.3 |
13 /15 |
RL3R2_HUMAN Relaxin-3 receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
VF0
|
E | 27.3 /31.2 |
11 /11 |
GPR34_HUMAN Probable G-protein coupled receptor 34 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
SER
|
E | 12.5 /30.7 |
8 /8 |
GPR34_HUMAN Probable G-protein coupled receptor 34 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
SER
|
E | 0.0 /29.5 |
7 /8 |
GP174_HUMAN Probable G-protein coupled receptor 174 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
UBL
|
E | 22.2 /29.5 |
18 /18 |
GP174_HUMAN Probable G-protein coupled receptor 174 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
UBL
|
E | 25.0 /30.8 |
12 /12 |
GPR34_HUMAN Probable G-protein coupled receptor 34,Tag |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
TJR
|
E | 21.4 /30.7 |
14 /14 |
GPR34_HUMAN Probable G-protein coupled receptor 34 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
MAE
|
A | 10.0 /30.7 |
10 /10 |
SUCR1_HUMAN Succinate receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
KW0
|
E | 22.2 /30.6 |
18 /18 |
GPR34_HUMAN Probable G-protein coupled receptor 34 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
KW3
|
D | 21.7 /30.6 |
23 /23 |
GPR34_HUMAN Probable G-protein coupled receptor 34 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
S |
SIN
|
A | 20.0 /30.1 |
5 /5 |
US28_HCMVA G-protein coupled receptor homolog US28 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
L |
SIN
|
A | 33.3 /28.6 |
6 /6 |
PD2R2_HUMAN D9IEF7_BPT4 D9IEF7_BPT4 PD2R2_HUMAN Prostaglandin D2 receptor 2, Endolysin chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
N |
SIN
|
A | 0.0 /28.6 |
3 /3 |
PD2R2_HUMAN D9IEF7_BPT4 D9IEF7_BPT4 PD2R2_HUMAN Prostaglandin D2 receptor 2, Endolysin chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
O |
SIN
|
A | 33.3 /28.6 |
3 /5 |
PD2R2_HUMAN D9IEF7_BPT4 D9IEF7_BPT4 PD2R2_HUMAN Prostaglandin D2 receptor 2, Endolysin chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
SIN
|
D | 10.0 /29.5 |
10 /11 |
C562_ECOLX SUCR1_HUMAN Soluble cytochrome b562,Succinate receptor 1,Oplop.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
SIN
|
A | 12.5 /29.5 |
8 /8 |
SUCR1_HUMAN Succinate receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
SIN
|
E | 10.0 /30.5 |
10 /11 |
SUCR1_HUMAN Succinate receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
H98
|
E | 16.7 /30.3 |
12 /12 |
Beta2 adrenergic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
5FW
|
E | 12.5 /30.3 |
8 /8 |
ADRB2_HUMAN Beta-2 adrenergic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
68H
|
E | 16.7 /30.2 |
12 /12 |
ADRB2_HUMAN Beta-2 adrenergic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
S12
|
A | 18.8 /30.1 |
16 /16 |
GPR34_HUMAN Probable G-protein coupled receptor 34 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
9P2
|
A | 25.0 /31.7 |
12 /12 |
C5AR1_HUMAN C5a anaphylatoxin chemotactic receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
U |
9P2
|
A | 0.0 /31.7 |
2 /2 |
C5AR1_HUMAN C5a anaphylatoxin chemotactic receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
9P2
|
B | 40.0 /30.7 |
5 /5 |
C5AR1_HUMAN C5a anaphylatoxin chemotactic receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
9P2
|
A | 25.0 /29.9 |
12 /12 |
C562_ECOLX C5AR1_HUMAN Soluble cytochrome b562, C5a anaphylatoxin chemota.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
EFD
|
A | 25.0 /29.9 |
16 /16 |
C562_ECOLX C5AR1_HUMAN Soluble cytochrome b562, C5a anaphylatoxin chemota.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
CAU
|
A | 18.8 /29.9 |
16 /16 |
ADRB2_HUMAN Beta-2 adrenergic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
ADP
|
E | 21.4 /29.8 |
14 /15 |
C562_ECOLX P2RY1_HUMAN Soluble cytochrome b562,P2Y purinoceptor 1,Soluble.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B |
6AD
|
A | 33.3 /33.2 |
18 /23 |
P2Y12_HUMAN C562_ECOLX P2Y12_HUMAN P2Y purinoceptor 12, Soluble cytochrome b562 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
6AD
|
A | 23.1 /29.8 |
13 /15 |
P2RY1_HUMAN P2Y purinoceptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
6AD
|
A | 31.2 /29.7 |
16 /16 |
P2Y12_HUMAN P2Y purinoceptor 12 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B |
BUR
|
A | 50.0 /29.7 |
10 /10 |
P2RY1_HUMAN RUBR_CLOPA P2RY1_HUMAN P2Y purinoceptor 1, Rubredoxin, P2Y purinoceptor 1.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
2ID
|
A | 13.3 /29.6 |
15 /17 |
P2RY1_HUMAN RUBR_CLOPA P2RY1_HUMAN P2Y purinoceptor 1,Rubredoxin,P2Y purinoceptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
KAZ
|
A | 20.0 /29.6 |
15 /16 |
SUCR1_RAT Succinate receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
Q4T
|
A | 26.7 /29.6 |
15 /15 |
SUCR1_RAT Succinate receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
K5Y
|
A | 25.0 /29.6 |
20 /20 |
D9IEF7_BPT4 ADRB2_HUMAN ADRB2_HUMAN Endolysin, Beta-2 adrenergic receptor chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
U9S
|
D | 12.5 /29.6 |
8 /8 |
C562_ECOLX SUCR1_HUMAN LUCI_OPLGR Soluble cytochrome b562,Succinate receptor 1,Oplop.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
U9S
|
A | 10.0 /29.5 |
10 /10 |
SUCR1_HUMAN Succinate receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
I |
FT4
|
A | 20.0 /29.5 |
5 /10 |
PD2R2_HUMAN D9IEF7_BPT4 D9IEF7_BPT4 PD2R2_HUMAN Prostaglandin D2 receptor 2, Endolysin chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
LPS
|
A | 25.0 /29.4 |
24 /25 |
GP174_HUMAN Probable G-protein coupled receptor 174 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
KJX
|
A | 20.0 /29.3 |
10 /10 |
GP183_HUMAN G-protein coupled receptor 183 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
ALE
|
A | 18.2 /29.3 |
11 /11 |
LYS_BPT4 ADRB2_HUMAN ADRB2_HUMAN Lysozyme, Beta-2 adrenergic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
35V
|
A | 21.4 /29.3 |
14 /14 |
D9IEF7_BPT4 ADRB2_HUMAN Beta-2 adrenergic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
GJ6
|
A | 15.4 /29.3 |
13 /13 |
ENLYS_BPT4 ADRB2_HUMAN ADRB2_HUMAN Endolysin,Beta-2 adrenergic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
G1I
|
A | 16.7 /29.3 |
12 /12 |
ENLYS_BPT4 ADRB2_HUMAN ADRB2_HUMAN Endolysin,Beta-2 adrenergic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
PFS
|
A | 27.3 /29.2 |
22 /22 |
PTAFR_HUMAN Platelet-activating factor receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
A1D54
|
F | 33.3 /29.2 |
9 /11 |
BRS3_HUMAN Bombesin receptor subtype-3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
XGD
|
E | 23.8 /29.1 |
21 /22 |
Q548Y0_HUMAN Hypocretin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
UYI
|
A | 0.0 /28.7 |
13 /15 |
GHSR_HUMAN Growth hormone secretagogue receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B |
FSY
|
A | 23.1 /28.6 |
13 /19 |
PD2R2_HUMAN D9IEF7_BPT4 D9IEF7_BPT4 PD2R2_HUMAN Prostaglandin D2 receptor 2, Endolysin chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B |
NRK
|
A | 6.7 /28.6 |
15 /15 |
OX2R_HUMAN Orexin receptor type 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
A1D6T
|
D | 30.0 /28.4 |
10 /20 |
Q5IFH6_HUMAN MCHR1_HUMAN C562_ECOLX C562_ECOL6 MCHR1 Melanin-concentrating hormone receptor 1,Soluble c.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
IMN
|
A | 18.2 /28.1 |
11 /11 |
PD2R2_HUMAN Prostaglandin D2 receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
OCA
|
F | 14.3 /28.0 |
7 /7 |
Soluble cytochrome b562 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
1KD
|
E | 0.0 /27.9 |
15 /19 |
GHSR_HUMAN Growth hormone secretagogue receptor type 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
JGX
|
A | 21.4 /27.8 |
14 /14 |
alpha1A-adrenergic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
A1D71
|
A | 14.3 /27.8 |
7 /7 |
HCAR1_HUMAN Hydroxycarboxylic acid receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
A1D5Q
|
A | 30.0 /27.2 |
10 /10 |
PD2R2_HUMAN Prostaglandin D2 receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
PG2
|
A | 26.7 /27.5 |
15 /15 |
PD2R2_HUMAN Prostaglandin D2 receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
P9X
|
E | 15.4 /24.5 |
13 /13 |
C562_ECOLX HCAR2_HUMAN Soluble cytochrome b562,Hydroxycarboxylic acid rec.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
3HO
|
A | 33.3 /27.3 |
6 /6 |
HCAR3_HUMAN Hydroxycarboxylic acid receptor 3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
CW3
|
E | 33.3 /27.2 |
12 /12 |
HCAR3_HUMAN Hydroxycarboxylic acid receptor 3 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B |
YSS
|
A | 33.3 /27.1 |
12 /17 |
PD2R2_HUMAN D9IEF7_BPT4 D9IEF7_BPT4 PD2R2_HUMAN Prostaglandin D2 receptor 2, Endolysin chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
8QX
|
A | 20.0 /27.0 |
15 /16 |
C562_ECOLX GHSR_HUMAN Chimera of Soluble cytochrome b562 and Growth horm.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
WJS
|
A | 13.3 /29.7 |
15 /15 |
GP174_HUMAN Probable G-protein coupled receptor 174 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
WJS
|
E | 23.5 /26.8 |
17 /18 |
P2Y10_HUMAN Putative P2Y purinoceptor 10 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
FI7
|
C | 11.8 /25.6 |
17 /17 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
FI7
|
E | 14.3 /24.5 |
21 /21 |
C562_ECOLX HCAR2_HUMAN Soluble cytochrome b562,Hydroxycarboxylic acid rec.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
FI7
|
A | 16.7 /24.5 |
18 /18 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
FI7
|
C | 15.4 /25.7 |
13 /13 |
ACM4_HUMAN HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
FI7
|
E | 7.1 /25.6 |
14 /14 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
IX8
|
E | 16.7 /24.4 |
12 /12 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
IX8
|
E | 16.7 /25.6 |
12 /12 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
AW9
|
E | 9.1 /25.6 |
11 /11 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
NIO
|
A | 11.1 /24.5 |
9 /9 |
HCAR2_HUMAN Hydroxy-carboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
NIO
|
A | 22.2 /24.5 |
9 /9 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
NIO
|
E | 18.2 /24.2 |
11 /11 |
ACM4_HUMAN HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
NIO
|
E | 20.0 /24.3 |
10 /10 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2,hydroxycarboxyli.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
NIO
|
E | 14.3 /25.6 |
7 /7 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
OJX
|
A | 15.4 /24.5 |
13 /13 |
HCAR2_HUMAN Human hydroxycarboxylic acid receptor 2,Hydroxycar.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
OJX
|
A | 20.0 /24.5 |
10 /10 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
OJX
|
C | 18.2 /25.5 |
11 /11 |
ACM4_HUMAN HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
OKL
|
A | 14.3 /24.5 |
14 /14 |
HCAR2_HUMAN Human hydroxycarboxylic acid receptor 2,Hydroxycar.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
OKL
|
A | 14.3 /24.5 |
14 /14 |
C562_ECOLX HCAR2_HUMAN Soluble cytochrome b562,Hydroxycarboxylic acid rec.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
OKL
|
E | 27.3 /24.3 |
11 /11 |
ACM4_HUMAN HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
OKL
|
E | 20.0 /24.5 |
15 /15 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2,hydroxycarboxyli.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
P8A
|
A | 13.3 /24.5 |
15 /15 |
C562_ECOLX HCAR2_HUMAN Soluble cytochrome b562,Hydroxycarboxylic acid rec.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
UR9
|
C | 33.3 /24.5 |
9 /9 |
ACM4_HUMAN HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
XOT
|
A | 22.2 /25.3 |
9 /9 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
XOT
|
A | 23.1 /24.5 |
13 /13 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
A1EAD
|
A | 26.7 /24.5 |
15 /15 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
3HR
|
E | 9.1 /24.4 |
11 /11 |
HCAR2_HUMAN Hydroxycarboxylic acid receptor 2 |
3.a3:asym_id for the contact molecule. 4.a4:asym_id for the template homologue. 5.identity[%]5:sequence identity between the query and the template homologue only for the contact residues. Number after the slash / is sequence identity for all the aligned region. 6.Ncon6:number of aligned contact residues for the query. Number after the slash / is number of contact residues in the template homologue. | |||||||
![]() |
|||||||
359 | pdb_id | contact mol | homologue | ||||
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
a3 | description | a4 | identity[%]5 | Ncon6 | description | |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
I |
ZN
|
A | 66.7 /35.9 |
3 /4 |
CCR2_HUMAN D9IEF7_BPT4 CCR2_HUMAN Chimera protein of CC chemokine receptor type 2 is.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
L |
CL
|
A | 50.0 /36.4 |
2 /3 |
PAR1_HUMAN LYS_BPT4 PAR1_HUMAN Proteinase-activated receptor 1, Lysozyme |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
S |
CL
|
A | 0.0 /36.5 |
1 /3 |
OPRM_MOUSE LYS_BPT4 OPRM_MOUSE Mu-type opioid receptor, lysozyme chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
J |
CL
|
A | 100.0 /98.7 |
2 /2 |
AGTR1_HUMAN C562_ECOLX AGTR1_HUMAN Type-1 angiotensin II receptor,Soluble cytochrome .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
K |
CL
|
A | 100.0 /98.7 |
1 /1 |
AGTR1_HUMAN C562_ECOLX AGTR1_HUMAN Type-1 angiotensin II receptor,Soluble cytochrome .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
L |
CL
|
A | 100.0 /98.7 |
3 /3 |
AGTR1_HUMAN C562_ECOLX AGTR1_HUMAN Type-1 angiotensin II receptor,Soluble cytochrome .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
P |
CL
|
B | 100.0 /98.7 |
2 /2 |
AGTR1_HUMAN C562_ECOLX AGTR1_HUMAN Type-1 angiotensin II receptor,Soluble cytochrome .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
Q |
CL
|
A | 33.3 /29.6 |
3 /3 |
SUCR1_RAT Succinate receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
MG
|
A | 33.3 /29.6 |
3 /5 |
D9IEF7_BPT4 ADRB2_HUMAN ADRB2_HUMAN Endolysin, Beta-2 adrenergic receptor chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
NI
|
A | 50.0 /29.6 |
2 /2 |
D9IEF7_BPT4 ADRB2_HUMAN ADRB2_HUMAN Endolysin, Beta-2 adrenergic receptor chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
M |
NA
|
A | 100.0 /36.4 |
3 /4 |
PAR1_HUMAN LYS_BPT4 PAR1_HUMAN Proteinase-activated receptor 1, Lysozyme |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
NA
|
A | 33.3 /29.3 |
3 /4 |
LYS_BPT4 ADRB2_HUMAN ADRB2_HUMAN Lysozyme, Beta-2 adrenergic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
U |
NA
|
A | 100.0 /33.3 |
3 /3 |
C562_ECOLX OPRD_HUMAN Soluble cytochrome b562, Delta-type opioid recepto.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
NA
|
A | 100.0 /33.6 |
3 /3 |
C562_ECOLX Soluble cytochrome b562,Delta-type opioid receptor.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
NA
|
A | 100.0 /33.8 |
3 /5 |
D9IEF7_BPT4 PAR2_HUMAN C562_ECOLX PAR2_HUMAN Lysozyme,Proteinase-activated receptor 2,Soluble c.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
NA
|
A | 100.0 /36.7 |
3 /4 |
CCR7_HUMAN NANA_STREE CCR7_HUMAN C-C chemokine receptor type 7,Sialidase A,C-C chem.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
NA
|
A | 100.0 /40.0 |
2 /5 |
CLTR1_HUMAN C562_ECOLX CLTR1_HUMAN Cysteinyl leukotriene receptor 1,Soluble cytochrom.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
NA
|
A | 66.7 /36.4 |
3 /3 |
LT4R1_HUMAN FLAV_DESVH LT4R1_HUMAN Leukotriene B4 receptor 1,Flavodoxin,Leukotriene B.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
NA
|
A | 80.0 /27.1 |
5 /6 |
PD2R2_HUMAN D9IEF7_BPT4 D9IEF7_BPT4 PD2R2_HUMAN Prostaglandin D2 receptor 2, Endolysin chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
J |
UNX
|
A | 0.0 /24.3 |
1 /1 |
HCAR2_HUMAN C562_ECOLX Hydroxycarboxylic acid receptor 2,Soluble cytochro.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
K |
UNX
|
A | 33.3 /24.3 |
3 /3 |
HCAR2_HUMAN C562_ECOLX Hydroxycarboxylic acid receptor 2,Soluble cytochro.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
L |
UNX
|
A | 0.0 /24.3 |
3 /3 |
HCAR2_HUMAN C562_ECOLX Hydroxycarboxylic acid receptor 2,Soluble cytochro.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
M |
UNX
|
A | 0.0 /24.3 |
3 /4 |
HCAR2_HUMAN C562_ECOLX Hydroxycarboxylic acid receptor 2,Soluble cytochro.. |
3.a3:asym_id for the contact molecule. 4.a4:asym_id for the template homologue. 5.identity[%]5:sequence identity between the query and the template homologue only for the contact residues. Number after the slash / is sequence identity for all the aligned region. 6.Ncon6:number of aligned contact residues for the query. Number after the slash / is number of contact residues in the template homologue. | |||||||
![]() |
|||||||
359 | pdb_id | contact mol | homologue | ||||
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
a3 | description | a4 | identity[%]5 | Ncon6 | description | |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C | 3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.]PYRAZOLE.. | G | 6.2 /28.0 |
16 /17 |
human ghrelin receptor |
3.a3:asym_id for the contact molecule. 4.a4:asym_id for the template homologue. 5.identity[%]5:sequence identity between the query and the template homologue only for the contact residues. Number after the slash / is sequence identity for all the aligned region. 6.Ncon6:number of aligned contact residues for the query. Number after the slash / is number of contact residues in the template homologue. | |||||||
![]() |
|||||||
359 | pdb_id | contact mol | homologue | ||||
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
a3 | description | a4 | identity[%]5 | Ncon6 | description | |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | AGTR1_HUMAN C562_ECOLX AGTR1_HUMAN AT118-H nanobody, Type-1 angiotensin II receptor, .. | A | 100.0 /94.7 |
18 /24 |
AGTR1_HUMAN C562_ECOLX AGTR1_HUMAN AT118-H nanobody, Type-1 angiotensin II receptor, .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | AGTR1_HUMAN C562_ECOLX AGTR1_HUMAN Nanobody AT206,Type-1 angiotensin II receptor,Solu.. | A | 100.0 /94.3 |
21 /31 |
AGTR1_HUMAN C562_ECOLX AGTR1_HUMAN Nanobody AT206,Type-1 angiotensin II receptor,Solu.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | AGTR1_HUMAN C562_ECOLX AGTR1_HUMAN Nanobody AT209,Type-1 angiotensin II receptor,Solu.. | A | 100.0 /94.2 |
13 /20 |
AGTR1_HUMAN C562_ECOLX AGTR1_HUMAN Nanobody AT209,Type-1 angiotensin II receptor,Solu.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | AGTR1_HUMAN C562_ECOLX AGTR1_HUMAN Nanobody AT206,Type-1 angiotensin II receptor,Solu.. | A | 100.0 /94.2 |
19 /24 |
AGTR1_HUMAN C562_ECOLX AGTR1_HUMAN Nanobody AT206,Type-1 angiotensin II receptor,Solu.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | OPRK_HUMAN LYS_BPT4 OPRK_HUMAN Kappa-type opioid receptor, Lysozyme[448 aa] | A | 60.0 /39.0 |
15 /19 |
OPRK_HUMAN LYS_BPT4 OPRK_HUMAN Kappa-type opioid receptor, Lysozyme |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | OPRK_HUMAN LYS_BPT4 OPRK_HUMAN Kappa-type opioid receptor, Lysozyme[448 aa] | A | 25.0 /39.0 |
16 /16 |
OPRK_HUMAN LYS_BPT4 OPRK_HUMAN Kappa-type opioid receptor, Lysozyme |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | C562_ECOLX AGTR2_HUMAN Chimera protein of Type-2 angiotensin II receptor .. | A | 12.5 /37.6 |
16 /18 |
C562_ECOLX AGTR2_HUMAN Chimera protein of Type-2 angiotensin II receptor .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | C562_ECOLX AGTR2_HUMAN Chimera protein of Type-2 angiotensin II receptor .. | B | 31.6 /37.9 |
19 /19 |
C562_ECOLX AGTR2_HUMAN Chimera protein of Type-2 angiotensin II receptor .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | CXCR4_HUMAN LYS_BPT4 CXCR4_HUMAN C-X-C chemokine receptor type 4, Lysozyme Chimera[.. | A | 14.3 /36.2 |
14 /23 |
CXCR4_HUMAN LYS_BPT4 CXCR4_HUMAN C-X-C chemokine receptor type 4, Lysozyme Chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | CXCR4_HUMAN LYS_BPT4 CXCR4_HUMAN C-X-C chemokine receptor type 4, Lysozyme Chimera[.. | A | 50.0 /37.1 |
11 /14 |
CXCR4_HUMAN LYS_BPT4 CXCR4_HUMAN C-X-C chemokine receptor type 4, Lysozyme Chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | CXCR4_HUMAN LYS_BPT4 CXCR4_HUMAN C-X-C chemokine receptor type 4, Lysozyme Chimera[.. | B | 25.0 /35.2 |
8 /13 |
CXCR4_HUMAN LYS_BPT4 CXCR4_HUMAN C-X-C chemokine receptor type 4, Lysozyme Chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | CXCR4_HUMAN C-X-C chemokine receptor type 4[284 aa] | C | 31.6 /36.5 |
19 /19 |
CXCR4_HUMAN C-X-C chemokine receptor type 4 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
I | CXCR4_HUMAN C-X-C chemokine receptor type 4[284 aa] | C | 37.5 /36.5 |
16 /16 |
CXCR4_HUMAN C-X-C chemokine receptor type 4 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D | CXCR4_HUMAN C-X-C chemokine receptor type 4[280 aa] | A | 36.4 /36.9 |
11 /11 |
CXCR4_HUMAN C-X-C chemokine receptor type 4 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | OPRM_MOUSE LYS_BPT4 OPRM_MOUSE Mu-type opioid receptor, lysozyme chimera[442 aa] | A | 17.6 /36.5 |
17 /29 |
OPRM_MOUSE LYS_BPT4 OPRM_MOUSE Mu-type opioid receptor, lysozyme chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | OPRK_HUMAN Kappa opioid receptor[276 aa] | A | 66.7 /36.0 |
6 /12 |
OPRK_HUMAN Kappa opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | Kappa-Opioid Receptor[285 aa] | A | 47.4 /36.4 |
19 /21 |
Kappa-Opioid Receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E | C562_ECOLX APJ_HUMAN Soluble cytochrome b562,Apelin receptor[298 aa] | D | 66.7 /35.6 |
3 /3 |
C562_ECOLX APJ_HUMAN Soluble cytochrome b562,Apelin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | OPRM_HUMAN Mu-type opioid receptor[288 aa] | A | 9.1 /34.4 |
11 /11 |
OPRM_HUMAN Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G | OPRM_HUMAN Mu-type opioid receptor[287 aa] | A | 8.3 /34.1 |
12 /12 |
OPRM_HUMAN Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | C562_ECOLX OPRX_HUMAN Fusion protein of Nociceptin receptor and cytochro.. | B | 33.3 /34.6 |
6 /7 |
C562_ECOLX OPRX_HUMAN Fusion protein of Nociceptin receptor and cytochro.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | C562_ECOLX OPRX_HUMAN Fusion protein of Nociceptin receptor and cytochro.. | B | 28.6 /34.6 |
14 /14 |
C562_ECOLX OPRX_HUMAN Fusion protein of Nociceptin receptor and cytochro.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | C562_ECOLX OPRX_HUMAN Fusion protein of Nociceptin receptor and cytochro.. | B | 30.8 /34.6 |
13 /20 |
C562_ECOLX OPRX_HUMAN Fusion protein of Nociceptin receptor and cytochro.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | C562_ECOLX OPRX_HUMAN Fusion protein of Nociceptin receptor and cytochro.. | A | 14.3 /33.6 |
7 /7 |
C562_ECOLX OPRX_HUMAN Fusion protein of Nociceptin receptor and cytochro.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | C562_ECOLX OPRX_HUMAN Fusion protein of Nociceptin receptor and cytochro.. | A | 27.8 /33.6 |
18 /18 |
C562_ECOLX OPRX_HUMAN Fusion protein of Nociceptin receptor and cytochro.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | C562_ECOLX OPRX_HUMAN Fusion protein of Nociceptin receptor and cytochro.. | A | 31.2 /33.6 |
16 /16 |
C562_ECOLX OPRX_HUMAN Fusion protein of Nociceptin receptor and cytochro.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
A | Delta opioid receptor[397 aa] | B | 46.2 /34.2 |
13 /16 |
Delta opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | Delta opioid receptor[361 aa] | A | 45.5 /32.5 |
11 /22 |
Delta opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F | OPRD_HUMAN Delta-type opioid receptor[289 aa] | A | 12.0 /32.5 |
25 /27 |
OPRD_HUMAN Delta-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B | C5AR1_HUMAN C5a anaphylatoxin chemotactic receptor 1[295 aa] | A | 27.3 /31.7 |
11 /11 |
C5AR1_HUMAN C5a anaphylatoxin chemotactic receptor 1 |
3.a3:asym_id for the contact molecule. 4.a4:asym_id for the template homologue. 5.identity[%]5:sequence identity between the query and the template homologue only for the contact residues. Number after the slash / is sequence identity for all the aligned region. 6.Ncon6:number of aligned contact residues for the query. Number after the slash / is number of contact residues in the template homologue. | |||||||
![]() |
|||||||
359 | pdb_id | contact mol | homologue | ||||
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
a3 | description | a4 | identity[%]5 | Ncon6 | description | |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
OLA
|
A | 25.0 /36.2 |
4 /4 |
CXCR4_HUMAN LYS_BPT4 CXCR4_HUMAN C-X-C chemokine receptor type 4, Lysozyme Chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
M |
OLA
|
B | 25.0 /36.2 |
8 /8 |
CXCR4_HUMAN LYS_BPT4 CXCR4_HUMAN C-X-C chemokine receptor type 4, Lysozyme Chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
N |
OLA
|
B | 0.0 /36.2 |
4 /4 |
CXCR4_HUMAN LYS_BPT4 CXCR4_HUMAN C-X-C chemokine receptor type 4, Lysozyme Chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
O |
OLA
|
B | 42.9 /36.2 |
7 /7 |
CXCR4_HUMAN LYS_BPT4 CXCR4_HUMAN C-X-C chemokine receptor type 4, Lysozyme Chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
OLA
|
A | 0.0 /33.3 |
3 /3 |
C562_ECOLX OPRD_HUMAN Soluble cytochrome b562, Delta-type opioid recepto.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
OLA
|
A | 66.7 /33.3 |
6 /6 |
C562_ECOLX OPRD_HUMAN Soluble cytochrome b562, Delta-type opioid recepto.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
OLA
|
A | 16.7 /33.3 |
6 /7 |
C562_ECOLX OPRD_HUMAN Soluble cytochrome b562, Delta-type opioid recepto.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
K |
OLA
|
A | 33.3 /33.3 |
3 /3 |
C562_ECOLX OPRD_HUMAN Soluble cytochrome b562, Delta-type opioid recepto.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
OLA
|
A | 100.0 /33.6 |
1 /1 |
C562_ECOLX Soluble cytochrome b562,Delta-type opioid receptor.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
I |
OLA
|
B | 33.3 /34.6 |
6 /6 |
C562_ECOLX OPRX_HUMAN Soluble cytochrome b562,Nociceptin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
J |
OLA
|
A | 0.0 /33.8 |
1 /1 |
C562_ECOLX OPRX_HUMAN Soluble cytochrome b562,Nociceptin receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
N |
OLA
|
A | 50.0 /34.8 |
2 /2 |
CCR9_HUMAN C-C chemokine receptor type 9 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
HA |
OLA
|
B | 25.0 /34.1 |
4 /5 |
CCR9_HUMAN C-C chemokine receptor type 9 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
OLA
|
A | 0.0 /31.7 |
1 /1 |
C5AR1_HUMAN C5a anaphylatoxin chemotactic receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
L |
OLA
|
A | 100.0 /31.7 |
1 /1 |
C5AR1_HUMAN C5a anaphylatoxin chemotactic receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
Q |
OLA
|
A | 25.0 /31.7 |
4 /4 |
C5AR1_HUMAN C5a anaphylatoxin chemotactic receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
S |
OLA
|
A | 25.0 /31.7 |
4 /4 |
C5AR1_HUMAN C5a anaphylatoxin chemotactic receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
X |
OLA
|
B | 0.0 /30.7 |
2 /2 |
C5AR1_HUMAN C5a anaphylatoxin chemotactic receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
J |
OLA
|
A | 0.0 /33.8 |
2 /2 |
CCR5_HUMAN RUBR_CLOPA CCR5_HUMAN C-C chemokine receptor type 5,Rubredoxin chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
OLA
|
A | 33.3 /36.8 |
6 /6 |
CCR2_HUMAN RUBR_CLOPA CCR2_HUMAN C-C chemokine receptor type 2,Rubredoxin,C-C chemo.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
OLA
|
A | 0.0 /36.8 |
1 /1 |
CCR2_HUMAN RUBR_CLOPA CCR2_HUMAN C-C chemokine receptor type 2,Rubredoxin,C-C chemo.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
I |
OLA
|
A | 0.0 /36.8 |
7 /10 |
CCR2_HUMAN RUBR_CLOPA CCR2_HUMAN C-C chemokine receptor type 2,Rubredoxin,C-C chemo.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
K |
OLA
|
A | 0.0 /36.8 |
3 /3 |
CCR2_HUMAN RUBR_CLOPA CCR2_HUMAN C-C chemokine receptor type 2,Rubredoxin,C-C chemo.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
OLA
|
A | 25.0 /29.6 |
4 /5 |
D9IEF7_BPT4 ADRB2_HUMAN ADRB2_HUMAN Endolysin, Beta-2 adrenergic receptor chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
OLA
|
A | 40.0 /32.5 |
5 /5 |
Delta opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
OLA
|
A | 33.3 /32.5 |
9 /9 |
Delta opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
OLA
|
B | 66.7 /34.2 |
3 /3 |
Delta opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
OLA
|
B | 50.0 /34.2 |
2 /2 |
Delta opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
L |
OLA
|
B | 33.3 /34.2 |
3 /3 |
Delta opioid receptor |
![]() ![]() ![]() ![]() ![]() |
![]() |
KA |
OLA
|
B | 100.0 /40.0 |
1 /5 |
CLTR1_HUMAN C562_ECOLX CLTR1_HUMAN Cysteinyl leukotriene receptor 1,Soluble cytochrom.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
I |
OLA
|
A | 33.3 /37.7 |
6 /7 |
CLTR2_HUMAN C562_ECOLX CLTR2_HUMAN Cysteinyl leukotriene receptor 2,Soluble cytochrom.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
M |
OLA
|
A | 25.0 /37.7 |
4 /4 |
CLTR2_HUMAN C562_ECOLX CLTR2_HUMAN Cysteinyl leukotriene receptor 2,Soluble cytochrom.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
Q |
OLA
|
A | 50.0 /37.7 |
4 /4 |
CLTR2_HUMAN C562_ECOLX CLTR2_HUMAN Cysteinyl leukotriene receptor 2,Soluble cytochrom.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
X |
OLA
|
A | 66.7 /37.7 |
3 /5 |
CLTR2_HUMAN C562_ECOLX CLTR2_HUMAN Cysteinyl leukotriene receptor 2,Soluble cytochrom.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
Z |
OLA
|
A | 0.0 /37.7 |
1 /2 |
CLTR2_HUMAN C562_ECOLX CLTR2_HUMAN Cysteinyl leukotriene receptor 2,Soluble cytochrom.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
OLA
|
A | 33.3 /36.4 |
6 /6 |
LT4R1_HUMAN FLAV_DESVH LT4R1_HUMAN Leukotriene B4 receptor 1,Flavodoxin,Leukotriene B.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
OLA
|
A | 50.0 /24.3 |
2 /2 |
HCAR2_HUMAN C562_ECOLX Hydroxycarboxylic acid receptor 2,Soluble cytochro.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
OLA
|
A | 50.0 /40.7 |
12 /13 |
APJ_HUMAN A7ZVB5_ECO24 APJ_HUMAN Apelin receptor,Soluble cytochrome b562 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
OLA
|
A | 50.0 /40.7 |
8 /8 |
APJ_HUMAN A7ZVB5_ECO24 APJ_HUMAN Apelin receptor,Soluble cytochrome b562 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
OLA
|
A | 33.3 /40.7 |
3 /3 |
APJ_HUMAN A7ZVB5_ECO24 APJ_HUMAN Apelin receptor,Soluble cytochrome b562 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
R |
1PE
|
A | 0.0 /36.5 |
1 /6 |
OPRM_MOUSE LYS_BPT4 OPRM_MOUSE Mu-type opioid receptor, lysozyme chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
O |
1PE
|
A | 100.0 /29.7 |
1 /1 |
P2RY1_HUMAN RUBR_CLOPA P2RY1_HUMAN P2Y purinoceptor 1, Rubredoxin, P2Y purinoceptor 1.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
EA |
1PE
|
A | 0.0 /37.7 |
3 /7 |
CLTR2_HUMAN C562_ECOLX CLTR2_HUMAN Cysteinyl leukotriene receptor 2,Soluble cytochrom.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
I |
1PE
|
A | 66.7 /40.7 |
3 /5 |
APJ_HUMAN A7ZVB5_ECO24 APJ_HUMAN Apelin receptor,Soluble cytochrome b562 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
J |
FMT
|
A | 44.4 /38.5 |
9 /9 |
C562_ECOLX AGTR2_HUMAN Soluble cytochrome b562,Type-2 angiotensin II rece.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
N |
PGE
|
A | 0.0 /33.3 |
3 /3 |
C562_ECOLX OPRD_HUMAN Soluble cytochrome b562, Delta-type opioid recepto.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
O |
PGE
|
A | 0.0 /33.3 |
1 /1 |
C562_ECOLX OPRD_HUMAN Soluble cytochrome b562, Delta-type opioid recepto.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
PGE
|
A | 28.6 /29.9 |
7 /7 |
C562_ECOLX C5AR1_HUMAN Soluble cytochrome b562, C5a anaphylatoxin chemota.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
M |
PGE
|
A | 100.0 /29.5 |
2 /2 |
PD2R2_HUMAN D9IEF7_BPT4 D9IEF7_BPT4 PD2R2_HUMAN Prostaglandin D2 receptor 2, Endolysin chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
AA |
PGE
|
A | 0.0 /37.7 |
1 /2 |
CLTR2_HUMAN C562_ECOLX CLTR2_HUMAN Cysteinyl leukotriene receptor 2,Soluble cytochrom.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
S |
TLA
|
A | 57.1 /33.3 |
7 /7 |
C562_ECOLX OPRD_HUMAN Soluble cytochrome b562, Delta-type opioid recepto.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
TLA
|
A | 50.0 /31.7 |
4 /9 |
C5AR1_HUMAN C5a anaphylatoxin chemotactic receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
TLA
|
A | 14.3 /31.7 |
7 /7 |
C5AR1_HUMAN C5a anaphylatoxin chemotactic receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
TLA
|
A | 75.0 /37.7 |
4 /7 |
CLTR2_HUMAN C562_ECOLX CLTR2_HUMAN Cysteinyl leukotriene receptor 2,Soluble cytochrom.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
P |
MPG
|
A | 60.0 /36.5 |
5 /5 |
OPRM_MOUSE LYS_BPT4 OPRM_MOUSE Mu-type opioid receptor, lysozyme chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
Q |
MPG
|
A | 50.0 /36.5 |
8 /8 |
OPRM_MOUSE LYS_BPT4 OPRM_MOUSE Mu-type opioid receptor, lysozyme chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
PCW
|
B | 46.2 /36.2 |
13 /13 |
C562_ECOLX CXCR3_HUMAN OPRK_HUMAN CXCR3_HUMAN Soluble cytochrome b562,C-X-C chemokine receptor t.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
OLC
|
A | 66.7 /36.2 |
3 /3 |
CXCR4_HUMAN LYS_BPT4 CXCR4_HUMAN C-X-C chemokine receptor type 4, Lysozyme Chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
OLC
|
A | 9.1 /36.2 |
11 /11 |
CXCR4_HUMAN LYS_BPT4 CXCR4_HUMAN C-X-C chemokine receptor type 4, Lysozyme Chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
OLC
|
A | 36.4 /36.2 |
11 /11 |
CXCR4_HUMAN LYS_BPT4 CXCR4_HUMAN C-X-C chemokine receptor type 4, Lysozyme Chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
OLC
|
B | 0.0 /36.2 |
1 /1 |
CXCR4_HUMAN LYS_BPT4 CXCR4_HUMAN C-X-C chemokine receptor type 4, Lysozyme Chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
J |
OLC
|
B | 100.0 /36.2 |
1 /1 |
CXCR4_HUMAN LYS_BPT4 CXCR4_HUMAN C-X-C chemokine receptor type 4, Lysozyme Chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
OLC
|
A | 0.0 /39.4 |
3 /3 |
CXCR4_HUMAN LYS_BPT4 CXCR4_HUMAN C-X-C chemokine receptor type 4, Lysozyme Chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
OLC
|
A | 60.0 /39.4 |
5 /5 |
CXCR4_HUMAN LYS_BPT4 CXCR4_HUMAN C-X-C chemokine receptor type 4, Lysozyme Chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
OLC
|
A | 42.9 /36.4 |
7 /7 |
PAR1_HUMAN LYS_BPT4 PAR1_HUMAN Proteinase-activated receptor 1, Lysozyme |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
OLC
|
A | 25.0 /36.4 |
4 /11 |
PAR1_HUMAN LYS_BPT4 PAR1_HUMAN Proteinase-activated receptor 1, Lysozyme |
![]() ![]() ![]() ![]() ![]() |
![]() |
G |
OLC
|
A | 0.0 /36.4 |
1 /8 |
PAR1_HUMAN LYS_BPT4 PAR1_HUMAN Proteinase-activated receptor 1, Lysozyme |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
OLC
|
A | 0.0 /39.0 |
4 /4 |
OPRK_HUMAN LYS_BPT4 OPRK_HUMAN Kappa-type opioid receptor, Lysozyme |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
OLC
|
A | 25.0 /33.6 |
4 /4 |
C562_ECOLX OPRX_HUMAN Fusion protein of Nociceptin receptor and cytochro.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
OLC
|
B | 28.6 /34.6 |
7 /7 |
C562_ECOLX OPRX_HUMAN Fusion protein of Nociceptin receptor and cytochro.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
I |
OLC
|
A | 11.1 /34.0 |
9 /9 |
CCR5_HUMAN RUBR_CLOPA CCR5_HUMAN Chimera protein of C-C chemokine receptor type 5 a.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
J |
OLC
|
A | 40.0 /34.0 |
5 /5 |
CCR5_HUMAN RUBR_CLOPA CCR5_HUMAN Chimera protein of C-C chemokine receptor type 5 a.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
O |
OLC
|
B | 66.7 /34.0 |
3 /3 |
CCR5_HUMAN RUBR_CLOPA CCR5_HUMAN Chimera protein of C-C chemokine receptor type 5 a.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
OLC
|
A | 50.0 /33.3 |
6 /6 |
C562_ECOLX OPRD_HUMAN Soluble cytochrome b562, Delta-type opioid recepto.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
I |
OLC
|
A | 20.0 /33.3 |
5 /5 |
C562_ECOLX OPRD_HUMAN Soluble cytochrome b562, Delta-type opioid recepto.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
M |
OLC
|
A | 50.0 /33.3 |
2 /2 |
C562_ECOLX OPRD_HUMAN Soluble cytochrome b562, Delta-type opioid recepto.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
W |
OLC
|
A | 54.5 /33.3 |
11 /11 |
C562_ECOLX OPRD_HUMAN Soluble cytochrome b562, Delta-type opioid recepto.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
OLC
|
A | 60.0 /33.2 |
5 /5 |
P2Y12_HUMAN C562_ECOLX P2Y12_HUMAN P2Y purinoceptor 12, Soluble cytochrome b562 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
OLC
|
A | 66.7 /33.6 |
9 /9 |
C562_ECOLX Soluble cytochrome b562,Delta-type opioid receptor.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
OLC
|
A | 0.0 /29.7 |
3 /3 |
P2RY1_HUMAN RUBR_CLOPA P2RY1_HUMAN P2Y purinoceptor 1, Rubredoxin, P2Y purinoceptor 1.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
J |
OLC
|
A | 11.1 /29.7 |
9 /9 |
P2RY1_HUMAN RUBR_CLOPA P2RY1_HUMAN P2Y purinoceptor 1, Rubredoxin, P2Y purinoceptor 1.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
N |
OLC
|
A | 10.0 /29.7 |
10 /10 |
P2RY1_HUMAN RUBR_CLOPA P2RY1_HUMAN P2Y purinoceptor 1, Rubredoxin, P2Y purinoceptor 1.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
OLC
|
A | 0.0 /34.9 |
2 /2 |
OPRM_MOUSE Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
OLC
|
A | 75.0 /34.9 |
4 /4 |
OPRM_MOUSE Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
OLC
|
A | 14.3 /35.9 |
7 /7 |
CCR2_HUMAN D9IEF7_BPT4 CCR2_HUMAN Chimera protein of CC chemokine receptor type 2 is.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
OLC
|
A | 14.3 /29.8 |
7 /7 |
Q80KM9_HCMV Envelope protein US28, nanobody 7 fusion protein |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
B |
OLC
|
A | 40.0 /31.7 |
5 /5 |
Q08BG4_DANRE ENLYS_BPT4 Q08BG4_DANRE Lysophosphatidic acid receptor 6a,Endolysin,Lysoph.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
OLC
|
A | 33.3 /29.9 |
3 /3 |
C562_ECOLX C5AR1_HUMAN Soluble cytochrome b562, C5a anaphylatoxin chemota.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
J |
OLC
|
A | 50.0 /32.0 |
4 /9 |
SUCR1_RAT Succinate receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
OLC
|
A | 100.0 /94.8 |
4 /4 |
AGTR1_HUMAN C562_ECOLX AGTR1_HUMAN Type-1 angiotensin II receptor,Soluble cytochrome .. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
M |
OLC
|
B | 50.0 /34.2 |
4 /4 |
Delta opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
OLC
|
A | 0.0 /40.0 |
2 /2 |
CLTR1_HUMAN C562_ECOLX CLTR1_HUMAN Cysteinyl leukotriene receptor 1,Soluble cytochrom.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
K |
OLC
|
A | 0.0 /40.0 |
3 /3 |
CLTR1_HUMAN C562_ECOLX CLTR1_HUMAN Cysteinyl leukotriene receptor 1,Soluble cytochrom.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
O |
OLC
|
A | 100.0 /37.7 |
1 /2 |
CLTR2_HUMAN C562_ECOLX CLTR2_HUMAN Cysteinyl leukotriene receptor 2,Soluble cytochrom.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
Q |
OLC
|
A | 25.0 /37.7 |
4 /4 |
CLTR2_HUMAN C562_ECOLX CLTR2_HUMAN Cysteinyl leukotriene receptor 2,Soluble cytochrom.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
OLC
|
A | 0.0 /37.1 |
1 /5 |
CLTR2_HUMAN C562_ECOLX CLTR2_HUMAN Cysteinyl leukotriene receptor 2,Soluble cytochrom.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
OLC
|
A | 50.0 /38.5 |
8 /9 |
C562_ECOLX AGTR2_HUMAN Soluble cytochrome b562,Type-2 angiotensin II rece.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
PO4
|
A | 0.0 /29.8 |
2 /2 |
US28_HCMVA G-protein coupled receptor homolog US28 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
PO4
|
A | 0.0 /34.9 |
3 /3 |
OPRM_MOUSE Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
P6G
|
A | 0.0 /34.9 |
7 /7 |
OPRM_MOUSE Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
P6G
|
A | 50.0 /34.9 |
4 /4 |
OPRM_MOUSE Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
J |
P6G
|
A | 100.0 /36.4 |
1 /9 |
LT4R1_HUMAN FLAV_DESVH LT4R1_HUMAN Leukotriene B4 receptor 1,Flavodoxin,Leukotriene B.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
PG4
|
A | 100.0 /34.9 |
2 /2 |
OPRM_MOUSE Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
NO3
|
A | 33.3 /34.8 |
6 /6 |
CCR5_HUMAN RUBR_CLOPA CCR5_HUMAN C-C chemokine receptor type 5,Rubredoxin,C-C chemo.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
ETA
|
E | 0.0 /34.7 |
1 /1 |
OPRM_HUMAN Mu-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
OLB
|
A | 42.9 /33.6 |
7 /7 |
C562_ECOLX OPRX_HUMAN Fusion protein of Nociceptin receptor and cytochro.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
OLB
|
B | 50.0 /34.6 |
2 /2 |
C562_ECOLX OPRX_HUMAN Fusion protein of Nociceptin receptor and cytochro.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
L |
PLM
|
A | 0.0 /34.3 |
2 /2 |
FPR2_HUMAN N-formyl peptide receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
M |
PLM
|
A | 20.0 /34.3 |
5 /5 |
FPR2_HUMAN N-formyl peptide receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
N |
PLM
|
A | 14.3 /34.3 |
7 /7 |
FPR2_HUMAN N-formyl peptide receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
PLM
|
E | 40.0 /35.7 |
5 /5 |
FPR1_HUMAN fMet-Leu-Phe receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
PLM
|
E | 40.0 /35.7 |
10 /10 |
FPR1_HUMAN fMet-Leu-Phe receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
PLM
|
F | 33.3 /34.3 |
3 /3 |
FPR2_HUMAN N-formyl peptide receptor 2 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
J |
PLM
|
A | 40.0 /35.9 |
5 /5 |
FPR1_HUMAN fMet-Leu-Phe receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
K |
PLM
|
A | 0.0 /32.5 |
2 /3 |
OPRD_HUMAN Delta-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
L |
PLM
|
A | 50.0 /32.5 |
4 /4 |
OPRD_HUMAN Delta-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
M |
PLM
|
A | 66.7 /32.5 |
3 /3 |
OPRD_HUMAN Delta-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
N |
PLM
|
A | 0.0 /32.5 |
2 /2 |
OPRD_HUMAN Delta-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
O |
PLM
|
A | 0.0 /32.5 |
8 /8 |
OPRD_HUMAN Delta-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
P |
PLM
|
A | 0.0 /32.5 |
1 /1 |
OPRD_HUMAN Delta-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
Q |
PLM
|
A | 0.0 /32.5 |
1 /1 |
OPRD_HUMAN Delta-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
R |
PLM
|
A | 0.0 /32.5 |
3 /3 |
OPRD_HUMAN Delta-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
S |
PLM
|
A | 0.0 /32.5 |
2 /2 |
OPRD_HUMAN Delta-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
K |
PLM
|
A | 33.3 /35.3 |
3 /3 |
OPRK_HUMAN Kappa-type opioid receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
L |
PLM
|
A | 40.0 /31.8 |
5 /5 |
C3AR_HUMAN C3a anaphylatoxin chemotactic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
M |
PLM
|
A | 20.0 /31.8 |
5 /5 |
C3AR_HUMAN C3a anaphylatoxin chemotactic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
PLM
|
A | 25.0 /29.7 |
4 /4 |
C5AR1_HUMAN C5a anaphylatoxin chemotactic receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
I |
PLM
|
A | 25.0 /36.9 |
8 /8 |
CML1_HUMAN Chemerin-like receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
J |
PLM
|
D | 0.0 /32.5 |
3 /3 |
LPAR6_HUMAN Lysophosphatidic acid receptor 6 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
NA |
CIT
|
B | 0.0 /30.7 |
2 /2 |
C5AR1_HUMAN C5a anaphylatoxin chemotactic receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
T |
MLI
|
A | 80.0 /34.8 |
5 /6 |
CCR9_HUMAN C-C chemokine receptor type 9 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
MLI
|
A | 20.0 /29.9 |
5 /8 |
C562_ECOLX C5AR1_HUMAN Soluble cytochrome b562, C5a anaphylatoxin chemota.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
MLI
|
A | 33.3 /29.9 |
6 /6 |
C562_ECOLX C5AR1_HUMAN Soluble cytochrome b562, C5a anaphylatoxin chemota.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
L |
UNL
|
A | 0.0 /30.1 |
2 /2 |
US28_HCMVA G-protein coupled receptor homolog US28 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
N |
UNL
|
A | 33.3 /30.1 |
3 /3 |
US28_HCMVA G-protein coupled receptor homolog US28 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
O |
UNL
|
A | 14.3 /30.1 |
7 /7 |
US28_HCMVA G-protein coupled receptor homolog US28 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
P |
UNL
|
A | 66.7 /30.1 |
3 /3 |
US28_HCMVA G-protein coupled receptor homolog US28 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
Q |
UNL
|
A | 33.3 /30.1 |
6 /6 |
US28_HCMVA G-protein coupled receptor homolog US28 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
UNL
|
A | 0.0 /29.8 |
2 /2 |
US28_HCMVA G-protein coupled receptor homolog US28 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
K |
MES
|
A | 50.0 /29.8 |
6 /6 |
Q80KM9_HCMV Envelope protein US28, nanobody 7 fusion protein |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
GOL
|
A | 75.0 /39.4 |
8 /8 |
CXCR4_HUMAN LYS_BPT4 CXCR4_HUMAN C-X-C chemokine receptor type 4, Lysozyme Chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
M |
GOL
|
A | 0.0 /32.0 |
5 /8 |
SUCR1_RAT Succinate receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
S |
PGO
|
A | 66.7 /28.6 |
3 /3 |
PD2R2_HUMAN D9IEF7_BPT4 D9IEF7_BPT4 PD2R2_HUMAN Prostaglandin D2 receptor 2, Endolysin chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
P |
PGO
|
A | 50.0 /29.5 |
4 /4 |
PD2R2_HUMAN D9IEF7_BPT4 D9IEF7_BPT4 PD2R2_HUMAN Prostaglandin D2 receptor 2, Endolysin chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
Q |
PGO
|
A | 0.0 /29.5 |
2 /2 |
PD2R2_HUMAN D9IEF7_BPT4 D9IEF7_BPT4 PD2R2_HUMAN Prostaglandin D2 receptor 2, Endolysin chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
R |
PGO
|
A | 25.0 /29.5 |
4 /4 |
PD2R2_HUMAN D9IEF7_BPT4 D9IEF7_BPT4 PD2R2_HUMAN Prostaglandin D2 receptor 2, Endolysin chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
1WV
|
A | 0.0 /29.3 |
4 /4 |
LYS_BPT4 ADRB2_HUMAN ADRB2_HUMAN Lysozyme, Beta-2 adrenergic receptor |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
SO4
|
A | 60.0 /36.5 |
5 /6 |
OPRM_MOUSE LYS_BPT4 OPRM_MOUSE Mu-type opioid receptor, lysozyme chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
SO4
|
A | 50.0 /36.5 |
4 /4 |
OPRM_MOUSE LYS_BPT4 OPRM_MOUSE Mu-type opioid receptor, lysozyme chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
SO4
|
A | 75.0 /36.5 |
4 /7 |
OPRM_MOUSE LYS_BPT4 OPRM_MOUSE Mu-type opioid receptor, lysozyme chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
SO4
|
A | 0.0 /36.5 |
4 /4 |
OPRM_MOUSE LYS_BPT4 OPRM_MOUSE Mu-type opioid receptor, lysozyme chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
N |
SO4
|
A | 33.3 /36.5 |
3 /3 |
OPRM_MOUSE LYS_BPT4 OPRM_MOUSE Mu-type opioid receptor, lysozyme chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
SO4
|
A | 75.0 /35.9 |
4 /4 |
CCR2_HUMAN D9IEF7_BPT4 CCR2_HUMAN Chimera protein of CC chemokine receptor type 2 is.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
E |
SO4
|
A | 100.0 /35.9 |
1 /4 |
CCR2_HUMAN D9IEF7_BPT4 CCR2_HUMAN Chimera protein of CC chemokine receptor type 2 is.. |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
C |
SO4
|
A | 0.0 /28.6 |
1 /8 |
PD2R2_HUMAN D9IEF7_BPT4 D9IEF7_BPT4 PD2R2_HUMAN Prostaglandin D2 receptor 2, Endolysin chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
F |
SO4
|
A | 50.0 /28.6 |
2 /4 |
PD2R2_HUMAN D9IEF7_BPT4 D9IEF7_BPT4 PD2R2_HUMAN Prostaglandin D2 receptor 2, Endolysin chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
G |
SO4
|
A | 60.0 /28.6 |
5 /7 |
PD2R2_HUMAN D9IEF7_BPT4 D9IEF7_BPT4 PD2R2_HUMAN Prostaglandin D2 receptor 2, Endolysin chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
SO4
|
A | 66.7 /28.6 |
3 /7 |
PD2R2_HUMAN D9IEF7_BPT4 D9IEF7_BPT4 PD2R2_HUMAN Prostaglandin D2 receptor 2, Endolysin chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
I |
SO4
|
A | 0.0 /28.6 |
1 /5 |
PD2R2_HUMAN D9IEF7_BPT4 D9IEF7_BPT4 PD2R2_HUMAN Prostaglandin D2 receptor 2, Endolysin chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
R |
SO4
|
A | 0.0 /29.6 |
3 /3 |
SUCR1_RAT Succinate receptor 1 |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
D |
FLC
|
A | 60.0 /27.1 |
5 /7 |
PD2R2_HUMAN D9IEF7_BPT4 D9IEF7_BPT4 PD2R2_HUMAN Prostaglandin D2 receptor 2, Endolysin chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
PEG
|
B | 50.0 /39.0 |
2 /3 |
OPRK_HUMAN LYS_BPT4 OPRK_HUMAN Kappa-type opioid receptor, Lysozyme |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
I |
PEG
|
B | 75.0 /39.0 |
4 /6 |
OPRK_HUMAN LYS_BPT4 OPRK_HUMAN Kappa-type opioid receptor, Lysozyme |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
S |
PEG
|
A | 0.0 /29.5 |
3 /3 |
PD2R2_HUMAN D9IEF7_BPT4 D9IEF7_BPT4 PD2R2_HUMAN Prostaglandin D2 receptor 2, Endolysin chimera |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
H |
PEG
|
A | 100.0 /24.3 |
1 /2 |
HCAR2_HUMAN C562_ECOLX Hydroxycarboxylic acid receptor 2,Soluble cytochro.. |
3.a3:asym_id for the contact molecule. 4.a4:asym_id for the template homologue. 5.identity[%]5:sequence identity between the query and the template homologue only for the contact residues. Number after the slash / is sequence identity for all the aligned region. 6.Ncon6:number of aligned contact residues for the query. Number after the slash / is number of contact residues in the template homologue. |